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ABSTRACT
Investigating Hemodynamic Responses to Electrical Neurostimulation
Sean Youra
Since the 1900s, the number of deaths attributable to cardiovascular disease has
steadily risen. With the advent of antihypertensive drugs and non-invasive surgical
procedures, such as intravascular stenting, these numbers have begun to level off. Despite
this trend, the number of patients diagnosed with some form of cardiovascular disease has
only increased. By 2030, prevalence of coronary heart disease is expected to increase
approximately by 18% in the United States. By 2050, prevalence of peripheral arterial
occlusive disease is expected to increase approximately by 98% in the U.S. No single
drug or surgical intervention offers a complete solution to these problems. Thus, a multifaceted regimen of lifestyle changes, medication, and device or surgical interventions is
usually necessary. A potential adjunct therapy and cost-effective solution for treating
cardiovascular disease that has been overlooked is neurostimulation.
Recent studies show that using neurostimulation techniques, such as
transcutaneous electrical nerve stimulation (TENS), can help to reduce ischemic pain,
lower blood pressure, increase blood flow to the periphery, and decrease systemic
vascular resistance. The mechanisms by which these hemodynamic changes occur is still
under investigation. The primary aim of this thesis is to elucidate these mechanisms
through a thorough synthesis of the existing literature on this subject. Neurostimulation,
specifically TENS, is thought to modulate both the metaboreflex and norepinephrine
release from sympathetic nerve terminals.
To test the hypothesis that TENS increases local blood flow, decreases mean
arterial pressure, and decreases cutaneous vascular resistance compared to placebo, in
which the electrodes are attached but no electrical stimulation is applied, a protocol was
developed to test the effect of neurostimulation on healthy subjects. Implementation of
this protocol in a pilot study will determine if neurostimulation causes significant changes
in blood flow using the most relevant perfusion measurement instrumentation. Before
conducting this study, pre-pilot comparison studies of interferential current therapy (IFC)
versus TENS, low frequency (4 Hz) TENS versus high frequency (100 Hz) TENS, and
electrode placement on the back versus the forearm were conducted. The only
statistically significant difference found was that the application of IFC on the back
decreased the reperfusion time, meaning that the time required to reach the average
baseline perfusion unit value after occlusion decreased. Further pre-pilot work
investigating these different modalities and parameters is necessary to ensure that
favorable hemodynamic changes can be detected in the pilot study.

Keywords: neurostimulation, hemodynamics, ischemia, transcutaneous electrical nerve
stimulation, interferential current therapy
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CHAPTER 1 – INTRODUCTION
1.1 Motivation
1.1.1 Peripheral Arterial Occlusive Disease
Peripheral arterial occlusive disease (PAOD) affects 8 to 12 million Americans,
which is expected to increase to about 19 million by 2050 [1-3]. PAOD affects patients
greater than 65 years of age significantly more than younger patients (Figure 1.1).

Figure 1.1: Prevalence of large-vessel PAOD (LV-PAD) in American patients among
selected age groups [4]
PAOD is one of three serious forms of ischemic disease; the other two are
cerebrovascular disease (CVD) and coronary artery disease (CAD). Ischemic disease is
responsible for more deaths in the United States than any other condition [5].
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The etiology behind all these forms of ischemic disease is atherogenesis, whereby
plaque builds up in the artery wall causing it to thicken, which eventually manifests itself
as atherosclerosis, i.e. mature, vulnerable plaques and stiffening of the vessel wall.
Atherogenesis is a positive feedback mechanism induced by turbulent shear stresses
within the arteries, usually at bifurcation points. Normally, changes in laminar shear is
resolved by outward or inward vessel remodeling. However, turbulent shear cannot be
adequately resolved at these bifurcation points, which continually activates the
endothelium, i.e. the shear induces a proinflammatory and procoagulant state. The
activation of the endothelium causes endothelial cells (ECs) to separate, express adhesion
proteins, such as intercellular adhesion molecule-1 (ICAM-1), and secrete cytokines,
such as monocyte chemoattractant protein-1 (MCP-1). MCP-1 triggers migration of
leukocytes into the intima and ICAM-1 binds the leukocytes to the ECs. These
leukocytes, specifically monocytes, mature into macrophages that phagocytose lipids, e.g.
low-density lipoproteins (LDLs) in the subendothelial space. After ingesting enough
LDLs, the macrophages transform into foam cells, which activate T-helper cells that
secrete interferon-γ (INF-γ) and tumor necrosis factor-α (TNF-α), both of which activate
the endothelium. In addition, TNF-α causes proliferation of smooth muscle cells (SMCs)
into the intima [6]. The proliferation of SMCs is one of the few events in this whole
cellular cascade that seems to have more of a reparative effect. Once in the intima, SMCs
produce matrix proteins, such as collagen and elastin, that contribute to the formation of
the fibrous cap over the plaque, providing structural stability to the lesion and reducing
the chance of it rupturing. Plaque mainly consists of calcium hydroxyapatite,
microvasculature, fibrous tissue, cholesterol, and fats, as well as inflammatory cells, such
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as T cells and macrophages, at the periphery of the plaque. Plaque composition and size
will eventually determine clinical prognosis for PAOD patients i.e. the smaller the size
and the more stable the plaque, the less severe the disease tends to be [7]. Over time,
plaque buildup changes the properties and physical appearance of the artery, as illustrated
in Figure 1.2.

Figure 1.2: Progression of atherosclerosis. Early atherosclerosis characterized by
increased plaque buildup within the vessel. Advanced atherosclerosis characterized by
proliferation of smooth muscle into the tunica intima, thickening of the tunica media, and
narrowing of the lumen [8]
In the case of PAOD and other ischemic diseases, endogenous revascularization is
impaired, i.e. arteriogenesis and angiogenesis, as well as vasodilation of the collateral
vessels [6]. The walls of the artery begin to harden and blood flow is impeded as the
condition worsens, causing ischemia and hypoxia. If exacerbated through continual
endothelium activation, thrombus formation may occur. Eventually, a myocardial
infarction (MI) or stroke may occur if the thrombus detaches from the vessel wall and
becomes an embolus that reaches the heart or brain, respectively. Both an MI and stroke
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can cause immediate death; even if they do not, the lifespan of the individual will be
drastically shortened.
The symptoms of atherosclerosis may remain silent until there is a significant
reduction in blood flow. If this occurs in the heart, symptoms such as angina pectoris and
shortness of breath tend to develop. Worsening angina pectoris, especially at rest, may
signal an imminent MI. If this occurs in the brain, a number of motor and neurological
problems may result, such as speech deterioration, breathing difficulty, and bladder
incontinence. As blood flow is further impeded, a stroke can occur, potentially causing
significant brain damage. If this occurs in the peripheral limbs, claudication is the most
common symptom, although many patients do not report this to their physician.
Claudication makes exercise and even normal daily activity difficult because of the
ischemic pain. Atherosclerosis may also occur in the kidneys i.e. ischemic nephropathy,
causing a host of symptoms such as uremia, dyspnea, hypertension, and kidney atrophy.
If hypoperfusion occurs in both kidneys, it may lead to renal failure. There are a number
of risk factors associated with ischemic disease including lack of exercise, poor nutrition,
smoking, hypertension, diabetes, obesity, and a family history of heart disease [5].
1.1.2 Treatments
The first-line treatment option against ischemic disease is usually lifestyle
changes. A patient’s diet can be carefully controlled by limiting their intake of calories,
fat, and sodium, so that blood pressure is reduced. Frequently, medication may also be
prescribed to lower cholesterol levels. Cholesterol medication includes statins, niacin,
bile-acid resins, fibric acid derivatives, and cholesterol absorption inhibitors. Many of
these lower LDL and triglyceride levels while slightly raising HDL levels [9]. The
rationale behind this is that lowering LDLs should cause less endothelial activation and
4

raising HDLs should increase reverse cholesterol transport, whereby HDLs remove lipids
from the surface of foam cells and transport them to the liver for processing [6]. Statins
are the most commonly prescribed cholesterol medications to treat atherosclerosis,
because they reduce all-cause mortality by about 14% and major adverse cardiac events
by more than 20% [10]. Other lifestyle changes include smoking cessation and a regular
exercise regimen that includes aerobic and resistance training, both of which can improve
pain-free walking distance in patients with PAOD [3, 11]. In fact, under direct
supervision, maximal walking distance may improve by an estimated 120% compared to
before the start of the exercise training program [12]. The mechanisms behind this
improvement in walking distance are attributed to enhanced vaso-responsiveness,
angiogenesis, and arteriogenesis [13, 14].
The advent of antihypertensive drugs has vastly improved our ability to control
many of the symptoms associated with atherosclerosis. Numerous variants of such drugs
exist on the market today including diuretics, adrenergic inhibitors such as beta-blockers,
angiotensin-converting-enzyme (ACE) inhibitors, and calcium channel blockers.
Diuretics have been prescribed for decades and are considered the “gold standard” of
antihypertensive drugs. Diuretics inhibit sodium and chloride reabsorption, which
decreases extracellular fluid volume, cardiac output, and peripheral vascular resistance.
In this way, they offer protection against myocardial infarction (MI), stroke, and heart
failure [15]. Beta-blockers suppress over-activity of the sympathetic nervous system
(SNS) by inhibiting beta-adrenergic norepinephrine receptors, which in turn reduces heart
rate (HR), cardiac output (CO), and blood pressure (BP). This is especially important for
both older individuals and PAOD patients who have an overactive SNS [16]. ACE
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inhibitors block the synthesis of angiotensin II in the renin-angiotensin system. Normally,
renin is converted into angiotensin I via angiotensinogen, and then subsequently
angiotensin I is converted into angiotensin II via ACE. Angiotensin II is a potent
vasoconstrictor, so ACE inhibitors reduce vasoconstriction [15]. They are commonly
prescribed to congestive heart failure (CHF) patients to lower mean arterial pressure
(MAP) and decrease systemic vascular resistance (SVR), and diabetic renal disease
patients to increase renal blood flow and sodium excretion rates, which improves renal
functioning [17, 18]. Calcium-channel blockers cause vasodilation by blocking L-type
calcium channels on arterial SMCs, which decreases BP, especially in the case of
hypertension. Calcium-channel blockers may also be combined with beta-blockers for
enhanced cardioprotective effects by further increasing blood flow and reducing BP [15].
As the disease progresses, a more aggressive surgical procedure may be needed. If
the plaque buildup is limited to one particular area, then balloon angioplasty combined
with stenting is commonly used. In this procedure, a balloon-tipped catheter is inserted
into the femoral artery and guided to the area of interest. The balloon is then inflated,
pushing the plaque up against the walls of the artery, which helps to improve blood flow
in the region by temporarily relieving stenosis. Another balloon with a mounted stent is
guided to the blockage and expanded in the same way. The stent is a permanent fixture
that is used to prevent elastic recoil of the vessel wall. The basic surgical procedure is
shown in Figure 1.3.
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Figure 1.3: A longitudinal section view of the insertion of a stent within an artery 1)
Balloon and stent are guided to the plaque location using a catheter guidewire 2) The
balloon is inflated expanding the stent and pushing the plaque up against the vessel wall
3) After deflating the balloon and removing the catheter, the stent remains in place and
integrates with the host tissue over time [19]
The advantage of this procedure is that it is minimally invasive, so the recovery time and
risk associated with the procedure are significantly reduced. However, there are many
cases in which angioplasty and stenting may not be a viable option. For example, if there
are multiple sites of blockage, if the artery itself it too small, or if there is a complete
blockage in the region, then peripheral artery bypass surgery may be necessary.
Peripheral artery bypass utilizes autologous, healthy functioning vessels, commonly the
great saphenous vein, or a synthetic graft such as Dacron or PTFE, to create a detour
around the blockage, as can be seen in Figure 1.4 [20]. Higher patency rates, i.e.
unobstructed and open vessel lumens, are typically seen when autologous vein grafts are
used compared to synthetic grafts [21]. As compared to angioplasty and stenting, this
procedure is much more invasive and expensive [22], but is associated with lower
amputation rates and higher survival rates [20].
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Figure 1.4: Peripheral artery bypass circumvents the occluded areas within the lower
extremities, allowing blood to reach the tissue downstream of the blockage [23]
All treatments available for atherosclerosis have limited efficacy, especially longterm. In the case of lifestyle changes, such as exercise, the progression of the disease may
be slowed and the quality of life may be improved, but in more severe cases, such as
critical limb ischemia, this may have little to no effect [21]. Statins carry many possible
side-effects including memory loss, liver damage, and hyperglycemia [9]. Both diuretics
and beta-blockers may cause insulin resistance, while calcium-channel blockers,
specifically Nifedipine, may provoke myocardial ischemia from reflex tachycardia [15].
Not only are peripheral bypass grafts more invasive and expensive than angioplasty and
stenting, but they also exhibit lower patency rates and higher reintervention rates [24],
hence stenting is now more commonly used in hospitals across the U.S. [25]. However,
even with stenting, there is a risk of possible infection at the catheter insertion site and
restenosis with bare-metal stents (BMS) [26]. The restenosis issue has been partially
ameliorated with the advent of drug-eluting stents (DES) that prevent restenosis [27].
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Specifically, paclitaxel-eluting stents exhibit the lowest vascular restenosis [28, 29], but
in-stent thrombosis is actually higher with DES following the removal of anti-platelet
agents compared to BMS [30, 31]. Because all current treatments suffer from various
inadequacies, novel treatment options must be explored and implemented.
As an adjunct to these treatments, neurostimulation may be used to treat the
symptoms of ischemic disease, specifically the pain caused by ischemia. Although
neurostimulation has been primarily used to treat chronic pain, such as low back pain,
many studies now suggest that it may also reduce ischemic pain by increasing blood flow
and restoring the oxygen supply to the affected area [32-37]. The mechanisms of these
effects are poorly understood, mainly because there is more than one process at work.
The neurostimulation technique, stimulation parameters, and patient selection all
influence the changes in blood perfusion. Nonetheless, the changes in SVR, BP, and
perfusion have potentially large implications for patients suffering from ischemic
diseases. For example, if neurostimulation can decrease vascular resistance and blood
pressure while maintaining adequate blood flow throughout the body, the workload on
the heart will be reduced and the condition may be prevented from worsening. Another
potential application of neurostimulation could be saving severely ischemic limbs from
being amputated by restoring some blood flow to the limbs. Thus, it would be worthwhile
to investigate whether neurostimulation can provide reliable analgesic, anti-ischemic
benefits to these affected patients.
1.2 Neurostimulation
Neurostimulation uses electrodes to stimulate excitable biological tissue, which in
turn modulates some part of the nervous system. Neurostimulation is the cornerstone of
neural engineering (neuroengineeering) and encompasses three subfields:
9

neuromodulation, stereotactic and functional neurosurgery, and functional electrical
stimulation (FES) [38]. Neuromodulation acts directly upon specific nerves or regions of
the brain by sending electrical, chemical, or optical signals via implantable, or nonimplantable, devices, which are used to treat neural disorders, including sensory and
motor disorders. Examples of such devices include spinal cord stimulators, deep brain
stimulators, and peripheral nerve stimulators, transcranial magnetic stimulators, and
implanted intraspinal drug delivery pumps [39]. About a century ago, neurosurgery
primarily entailed the ablation of damaged or dysfunctional nervous tissue to treat
nervous system disorders, such as Parkinson’s, epilepsy, and tremors, pain from spinal
disc herniation, injuries of the peripheral nerves, spinal cord or head trauma, and
psychiatric illnesses, but electrical neurostimulation is now more commonly used to treat
these disorders. However, neurosurgery may still selectively be used depending on the
patient criteria and if the patient presents any contraindications for the particular
neurostimulation device. FES pertains mostly to restoring some function in the limbs
following injury or ischemia by selectively stimulating the damaged nerves; this subfield
also focuses on auditory and visual prostheses [38]. Because neuromodulation and FES
are used for similar applications, the two terms are commonly used interchangeably, but
the procedures involved in terms of leads and electrode placement do differ. Throughout
the course of this thesis, the term “neurostimulation” will be used to refer specifically to
neuromodulation that utilizes electrical impulses rather than neurosurgery or FES.
There are many neurostimulation techniques available today, and most focus on
pain management. Some of the most common methods are transcutaneous electrical
nerve stimulation (TENS), spinal cord stimulation (SCS), electroacupuncture (EA), and
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interferential current stimulation (IFC), all of which will be discussed in much greater
detail in Chapter 2. To effectively manage and reduce the patient’s pain, certain
parameters must be carefully adjusted to provide the maximum analgesic benefits. These
parameters include stimulus intensity, pulse width, and frequency. The intensity is the
relative strength of the stimulation, measured in milliamps (mA) or volts (V) based on the
stimulation unit design, i.e. a constant current unit provides variable voltage to maintain
the current and outputs intensity in mA, while a constant voltage unit provides variable
current to maintain the voltage and outputs intensity in V. This is the most variable
parameter, since the intensity range varies among different stimulation units. Electrode
placement is the main factor driving these difference,s e.g. different intensities will be
required for treating chronic back pain depending on whether the electrodes are applied
on the surface of the skin or implanted within the epidural space of the spinal cord. There
is considerable individual variation with intensity as well, because of differences in
sensory and motor thresholds, so this parameter should be first adjusted by the physician
to avoid any pain or discomfort. The intensity “feeling” will be strongly influenced by
both the pulse width and frequency. Pulse width is the duration of a pulse, measured in
microseconds (µs). This parameter usually ranges between 100 and 400 µs. Frequency is
the rate the pulses are transmitted, measured in hertz (Hz, cycles per second). A range of
20 to 120 Hz is common for this parameter, although much higher frequencies may be
used for SCS for improved paresthesia, but this comes with the cost of higher power
requirements [38, 40]. The lowest possible settings for all these parameters are usually
chosen to conserve battery life, especially in the case of implanted stimulators [38].
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Comprehension of the gate control theory is required to understand how
neurostimulation elicits an analgesic effect. The gate control theory was first published
by Ronald Melzack and Patrick Wall in 1965. Before this time, there were two mutually
exclusive theories, the specificity theory and the pattern theory, both of which attempted
to explain the mechanisms underlying pain. The specificity theory stated that pain is very
similar to vision or hearing in that it has its own specific central and peripheral neural
pathways; these pathways are direct “transmission lines” without modulation from any
other systems [41]. According to this theory, a nociceptor would only be activated by
noxious stimuli and the signal would then travel along a pain fiber up to specific “pain
centers” in the brain. Large afferent fibers were responsible for touch sensations while
small afferent fibers were responsible for pain sensations. Evidence for this theory comes
from Schiff and Woroschiloff’s work in which they transected the grey matter, which
effectively eliminated painful sensations but not touch. Similarly, they transected the
posterior white matter, which eliminated touch sensations but not pain [42, 43]. The
specificity theory continued to evolve when Sherrington provided a framework for the
specificity of neurons to touch, temperature, and pain, and described how receptors lower
the excitability threshold for a given stimulus and raise it for others. This inadvertently
resolved the disparity between the specificity theory and the intensity theory, another
popular pain theory of the time, which stated that pain resulted from excessive
somatosensory stimulation [43, 44]. The pattern theory, as proposed by Nafe, stated that
sensation occurs as a result of specific patterns of neural firing. The stimulus type and
intensity is encoded in the “spatial and temporal profile”, i.e. where the stimulus occurs
and the duration of the stimulus. This theory was substantiated by Weddell and Sinclair’s
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work who observed that intense stimulation of various nerve fibers would all cause the
sensation of pain [43, 45, 46]. A depiction of both the pattern theory and the specificity
theory is shown in Figure 1.5.

Figure 1.5: Schematic diagrams of both the pattern theory and specificity theory. In the
pattern theory, nonspecific receptors in the skin respond to both noxious and innocuous
stimuli, which are transmitted to the dorsal root ganglion (DRG) neurons, each of which
has different levels of responsiveness to stimuli; the pattern of firing determines the
stimulus type. In the specificity theory, each stimulus type is encoded in its own unique
pathway e.g. a noxious stimulus is transmitted to DRG nociceptors and then to dorsal
horn nociceptive neurons [43]
However, each theory had substantial weaknesses in that they could not
adequately explain the mechanisms behind certain pathological pain states, such as
phantom limb pain or peripheral neuralgias, i.e. sharp pain due to irritation or injury of a
nerve. The specificity theory assumed that a “pain receptor” must only sense pain and
that there is a specific brain center that deals only with pain. Although it is true that Aδfibers respond to high intensity stimulation such as sharp pain, these fibers also respond
to thermal and mechanical stimuli [47]. Similarly, there are many regions in the brain and
spinal cord, such as the dorsal horn, thalamus, periaqueductal grey (PAG), parabrachial
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area (PB), and rostral ventromedial medulla (RVM), that modulate and control the
sensation of pain, not one single center [48, 49]. The most glaring limitation with Nafe’s
pattern theory was his assumption that all fibers were alike and any type of stimulus
would activate nonspecific receptors; however, there is a high degree of specialization
between receptors and fibers [50, 51]. For example, activation of transient receptor
potential vanilloid receptor-1 (TRPV1), through the application of heat, selectively
activates C-fibers [47, 52]. Although reasonably sound, both theories still lacked unity
and could not adequately explain the etiology behind many neuropathies and variations in
pain sensation. This limitation was addressed by the gate control theory.
The gate control theory basically unites the specificity theory and the pattern
theory by stating there are specific fibers and receptors, but there is also a “control
center” that modulates all somatosensory stimuli before an individual experiences a
sensation. This “control center” or gate control system is the substantia gelatinosa (SG) in
the dorsal horn of the spinal cord, as illustrated in Figure 1.6.

.
Figure 1.6: Cross-section of the spinal cord at the cervical level depicting the various
tracts and regions; the substantia gelatinosa is located within the dorsal horn (upper
right) [53]
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The SG modulates incoming nerve impulses before the impulse reaches the first central
transmission cells (T cells). Neurons in the SG have an inhibitory effect on the primary
afferent terminals of the T cells. This inhibitory effect is enhanced by increased activity
from Aα-fibers and Aβ-fibers and reduced by increased activity from Aδ-fibers and Cfibers [43]; depictions of these various fiber types are shown in Figure 1.7.

Figure 1.7: Average diameters and conduction velocities for primary afferent neurons;
more myelination increases conduction velocity [54]
Aβ-fibers have low activation thresholds and transmit tactile information. Both Aδ-fibers
and C-fibers have high activation thresholds and transmit nociceptive information, which
may originate from thermal, chemical, or mechanical noxious stimuli [47]. C-fibers are
associated with longer, throbbing pain while Aδ-fibers are associated with fast, sharp
pain. In the absence of a stimulus or from activation of Aβ-fibers, the gate remains
“closed”, i.e. pain perception does not occur, because the inhibitory effect dominates and
prevents activation of the T cells. The activation of C-fibers causes the gate to “open”,
i.e. pain perception does occur, because the inhibitory effect is reduced, which activates
the T cells, allowing the noxious stimulus to reach the “action system” that is responsible
15

for painful sensations and responses. If the noxious stimulus intensity increases, the firing
of the T cells increases slowly. If this stimulus is prolonged, the Aβ-fibers begin to adapt
while C-fiber activity continues to increase, further increasing the firing of the T cells
[41]. A depiction of how this gate control system works is shown in Figure 1.8.

Figure 1.8: Schematic of the gate control system where A-fibers and C-fibers innervate
the SG and first central transmission (T) cells. The SG inhibitory effect on the T cells is
influenced by the relative activities of the A-fibers and C-fibers. This, combined with
central control mechanisms, leads to some sensory and response output by the action
system [43]
Our understanding of pain mechanisms has changed since the gate control theory
was first proposed, yet many of its tenets and assumptions hold true. For example, we
now know where each fiber type terminates in the different grey matter layers of the
dorsal horn, i.e. the Rexed laminae of the dorsal horn. Both Aδ-fibers and C-fibers
terminate in laminae I, II and V, while Aβ-fibers terminate in laminae III – V [49].
Within the dorsal horn, various neuron types exist. Nociceptive-specific (NS) neurons
synapse with Aδ-fibers and C-fibers, proprioceptive neurons synapse with Aβ-fibers, and
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wide dynamic range (WDR) neurons synapse with all three fiber types. The frequency of
action potentials elicited from WDR neurons is dependent upon the intensity of the
stimulus, so that a noxious stimulus may be differentiated from a non-noxious stimulus
based on the rate of firing of WDR neurons, i.e. noxious stimuli elicit higher rates of
firing from WDR neurons. In addition, excitatory and inhibitory interneurons exist in the
dorsal horn. The inhibitory interneurons release gamma-aminobutyric acid (GABA),
which decreases the activity of NS and WDR neurons [47]. The excitatory interneurons
primarily release glutamate, which increases activity of post-synaptic spinal neurons.
Specifically, it causes depolarization of a-amino-3-hydroxy 5-methyl-4isoxazeloproprionic acid (AMPA) receptors, N-methyl-D-aspartate (NMDA) receptors,
and G-protein coupled metabotropic receptors, all of which are targets for current drug
and other therapeutic interventions [47, 55-57]. We also know that the “action system”
that Melzack and Wall described is in fact different regions of the brain that also serve as
“control centers” for pain modulation. For example, neurokinin I (NK1)-expressing
neurons from lamina I, i.e. NS neurons, synapse in the thalamus, PAG, PB, and RVM
[49]. Descending pathways, such as from the RVM, project back to the dorsal horn,
which is where the effect of “central control” occurs [48], although these descending
pathways are not activated without sufficient stimulation from afferent fibers. The limbic
system is responsible for the emotional experience associated with pain, which affects the
descending pathways and the response of the spinothalamic tract (STT) neurons.
Projection neurons from laminae III – VI, i.e. WDR neurons, synapse primarily with the
thalamus and provide the majority of the sensory information that reaches the brain. From
the thalamus, somatosensory information travels to the cortex where various regions may
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be activated depending on the stimulus [47]. The anatomical projections of the primary
afferent fibers and their associated innervation sites are shown in Figure 1.9.
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Figure 1.9: Diagram of how somatosensory information travels from the periphery to the
brain. All fibers travel up through the dorsal root ganglion (DRG) and synapse at the
dorsal horn within different laminae as well as with the wide dynamic range (WDR)
neurons; only C-fibers and Aδ-fibers synapse with nociceptive specific (NS) neurons.
Projection neurons, shown as black arrows, innervate the periaqueductal grey (PAG),
parabrachial area (PB), and thalamus. Descending pathways, shown as yellow arrows,
project from the rostral ventromedial medulla (RVM) and other brainstem regions to the
dorsal horn [47]
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The strength of the modern version of the gate control theory is that it can explain
the mechanisms of many different neuropathies and provides a framework for potential
therapies. In the case of hyperalgesia or allodynia, “central sensitization” occurs when the
STT neurons become hyperexcitable, so that a noxious stimulus is amplified or a nonnoxious stimulus evokes pain [58]. Central sensitization is thought to occur from the
activation of NMDA receptors on WDR neurons by intense stimulation of C-fibers
through the release of glutamate and substance P. This depolarization temporarily
eliminates the Mg2+ block on the NMDA receptors, making the WDR neurons more
responsive to Aβ-fiber stimulation [58]. Tissue inflammation involves both central
sensitization and “peripheral sensitization”, where the sensitivity of C-fiber nerve
terminals increases from the release of histamine, prostaglandins, and other mediators,
and this increased sensitivity is responsible for triggering the spinal hyperexcitable state
[59]. In chronic inflammatory diseases, the central sensitization can be sustained
indefinitely as long as the noxious stimulus is present [60]. Nerve injury, from phantom
limb pain, causalgia, diabetic nephropathy, etc., causes ectopic discharge at the site of
injury, in the DRG, and from collateral sprouts of adjacent afferents, specifically within
the cell bodies, i.e. somas, and the axons of the neurons [61]. Aδ, Aβ, and C-fibers can all
develop ectopic discharge, which evokes central sensitization, leading to allodynia [58].
This explains why amputee patients may feel pain in their residual limb if pressure is
applied. Descending pathways from the brain counteract this hyperexcitability of dorsal
horn neurons by releasing neurotransmitters, mainly serotonin and norepinephrine, both
of which are associated with anti-nociception. Many antidepressant drugs, such as
tricyclic antidepressants (TCAs) and serotonin-norepinephrine reuptake inhibitors

20

(SNRIs), reduce the reuptake of one or both of these neurotransmitters, and thus can be
used for analgesic purposes as well [47, 62]. The activity of different brain regions can
also be modulated through psychological interventions, e.g. hypnosis or cognitive
behavioral therapy can reduce the pain sensation by influencing cognitive control from
the cerebral cortex and limbic system [43]. Most importantly, electrotherapy, specifically
neurostimulation, can be used to reduce chronic pain symptoms. As stated before, the
gate control theory explains how a noxious stimulus carried by Aδ-fibers and C-fibers
reaches the brain by overcoming the inhibitory effect of the dorsal horn interneurons and
activating the projection neurons. Neurostimulation uses electrodes that directly stimulate
the Aβ-fibers through electrical impulses, which blocks the noxious stimulus carried by
the C-fibers, such that the inhibitory effect of the dorsal horn interneurons is enhanced,
preventing the projection neurons from firing; the end result is analgesia.
1.3 Overview and Aims of the Thesis
Neurostimulation may offer yet another treatment option for patients suffering
from ischemic disease. It possesses several advantages over current treatment methods
including cost-effectiveness, ease of use, no major side-effects if applied correctly, noninvasiveness (for certain modalities), less of a need for oral medication such as
analgesics, and potential for long-lasting effectiveness. However, much is still to be
learned about how this stimulation actually causes hemodynamic changes. Moreover, the
results from multiple studies involving neurostimulation and its effects on blood flow are
conflicting [32, 36, 63-68]. To date, there is no real consensus on which neurostimulation
technique offers the best treatment, mainly because the parameters used differ widely
throughout the literature and most studies have not focused on direct comparisons for
different disease states. Also, large-scale, multicenter studies have been conducted on
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individuals experiencing chronic pain and ischemic pain, and have found significant
reductions in both using these different stimulation techniques, but have not investigated
how the hemodynamics change [69-73].
In terms of hemodynamics, blood flow is the most sensitive and most difficult
parameter to measure. The modality that is used to measure blood flow, calibration of the
equipment, location of measurement, environmental conditions, investigator’s skill with
the equipment, and software that is used to acquire the data may all impact the results of
the study. The application itself may warrant the use of a specific modality, such as
measuring cutaneous blood flow in the periphery versus measuring myocardial perfusion.
However, there are no formal guidelines established for what perfusion instrumentation
works most effectively for a given application.
This thesis will take the first steps toward bridging the gap between palliative
neurostimulation and hemodynamic changes. By uncovering the mechanisms underlying
these changes, and the set of parameters that produce the greatest favorable changes,
neurostimulation units can be utilized more efficiently to maximize the analgesia and
minimize ischemia. A pilot study in healthy humans will test the hypothesis that
neurostimulation provides ischemic relief through increases in cutaneous blood flow and
evokes systemic changes, such as lowering blood pressure, using the most “ideal”
neurostimulation technique and perfusion measurement instrumentation.
The specific aims of this thesis are as follows:
 Aim 1: Outline the possible mechanisms of neurostimulation- induced
hemodynamic changes, i.e. vasodilation and reduced metaboreflex, and
formulate a hypothesis to test these changes
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 Aim 2: Develop a protocol for a non-significant risk study in healthy
volunteers
 Aim 3: Optimize the study design through pre-pilot experiments
In conclusion, this thesis will provide background to perform a pilot study where
neurostimulation is applied to measure both hemodynamic endpoints and ischemic pain.
Before outlining the pilot study design, neurostimulation devices and perfusion
measurement instrumentation that are currently available will be discussed in detail.
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CHAPTER 2 – NEUROSTIMULATION TECHNIQUES
2.1 Transcutaneous Electrical Nerve Stimulation
Transcutaneous electrical nerve stimulation (TENS) is a noninvasive
neurostimulation technique that uses a battery-operated unit to send electrical impulses
through the skin via attached electrodes. The intensity, duration, frequency, and pulse
width can all be adjusted on the TENS unit. A dual channel system with four electrodes is
commonly used to stimulate different regions (Figure 2.1).

Figure 2.1: A dual-channel TENS unit consisting of four electrodes positioned over
different regions of the body for treating peripheral pain [74]
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The use of TENS requires a prescription from a physician for the treatment of
symptomatic pain and management of chronic pain; the indications also include
postoperative and posttraumatic pain. The contraindications include undiagnosed pain,
patients with implanted electronic devices such as pacemakers, patients who are currently
pregnant, and patients who have a history of epilepsy [75]. Typical nerves that are
stimulated with TENS include the ulnar, median, radial, tibial, and peroneal nerves,
which may be stimulated directly by applying the electrodes over the desired nerve or
indirectly by applying the electrodes on the back over a specific dermatome that
innervates the desired region. TENS may also be combined with another
neurostimulation technique such as spinal cord stimulation [76].
The mechanism of action for TENS in the mitigation of pain involves both the
peripheral nervous system (PNS) and central nervous system (CNS), as discussed in
Section 1.2. In addition to the gate control theory (Figure 1.8), low (< 10 Hz) frequency
TENS is associated with activation of µ-opioid receptors while high (> 50 Hz) frequency
TENS is associated with activation of δ-opioid receptors in the spinal cord and rostral
ventromedial medulla. Furthermore, the fiber type that is activated by TENS depends on
the level of intensity applied, i.e. sensory intensity up to and including motor threshold
activates the Aβ-fibers, while intensities twice above motor threshold activate Aδ-fibers,
which can also cause analgesia by activating descending inhibitory pathways, specifically
the PAG and RVM [69, 77-79]. These relative levels of intensity and the associated fibers
that they activate are true for the other neurostimulation techniques that will be discussed.
Sensory intensity is defined as the perception of the electrical impulses without muscle
contraction, while intensity at motor threshold, i.e. motor intensity, elicits muscle
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contraction without painful sensation. If high frequency TENS is used, this is usually
accompanied by sensory intensity, whereas low frequency TENS will usually be
accompanied by motor intensity [69].
A summary of various studies involving TENS and its effects on the
cardiovascular system are shown in Table A.1 of Appendix A. All studies were
conducted on human subjects, most of them healthy. In most cases, the intensity was
adjusted to sensory intensity with an average pulse width of 200 µs, frequency of 100 Hz,
and treatment duration of 15 minutes. The electrodes were applied either directly over the
ischemic area, e.g. forearm or chest, or on the specific dermatomes that innervate the
ischemic area, e.g. C2 – C3. Reductions in MAP and cutaneous vascular resistance
(CVR) as well as increases in cutaneous blood flow (CBF) occurred in many of these
studies [33, 63, 66, 67, 80, 81].
A possible mechanism of action for these hemodynamic changes may be that
TENS inhibits the sympathetic nervous system (SNS), possibly through a reflex response.
It may also be causing local vasodilation through release of endogenous vasodilators
from DRG neurons, such as substance P, which binds to NK-1 receptors located
throughout the central and peripheral nervous systems, or calcitonin gene-related peptide
(CGRP), which binds to CGRP-1 receptors on the endothelium [82, 83], and/or
decreasing arterial levels of norepinephrine/epinephrine [36]. The last study by
Indergand, et. al. stands in contrast to the rest of the studies, as no changes in MAP,
CVR, or CBF were found with application of TENS using similar parameters to the other
studies. This contradiction is not unique for studies investigating the use of
neurostimulation devices and their effects on hemodynamics; SCS, EA, and IFC also
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produce varying results [35, 84-86], making it difficult to establish whether
neurostimulation induces beneficial hemodynamic changes.
2.2 Spinal Cord Stimulation
Spinal cord stimulation (SCS) was first used in 1967 by Dr. Norman Shealy and
colleagues. It involves the implantation of electrodes in the epidural space which
transmits current across the spinal cord or near the nerve roots. The electrode-containing
leads are connected to an implanted pulse generator (IPG) or a radio-frequency (RF) unit,
both of which serve as pulse generators that drive the current. The IPG or RF unit is
usually implanted in the lower abdominal area or in the gluteal region, but can also be
implanted between the shoulder blades for cervical or occipital generators [38]. The IPG
has its own battery, so replacement is eventually required, even if it is rechargeable. The
RF unit has an external battery that can be easily replaced. It consists of an antenna
attached to the patient’s skin that wirelessly communicates with the implanted receiver.
An RF unit is usually preferable in cases where the patient will require high power
settings for their pain treatment, although newer rechargeable IPGs are quickly replacing
their use [87, 88]. A programmer allows adjustment of the stimulation settings by the user
or surgeon. The leads may be cylindrical or paddle type. In both cases, a trial is
implemented to ensure that the electrically- induced paresthesia completely masks the
painful region, which is referred to as concordant paresthesia [89]. A successful trial is
one that provides at least a 50% reduction in pain, which can be assessed using the Visual
Analog Scale for pain intensity [90, 91]. Current steering is a newer advancement in SCS
lead technology, in which multiple independent current sources and sinks are used, and
the current from either the source or sink is gradually decreased from one electrode and
increased to another or vice versa; this allows for more efficient programming, such that
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the area of pain coverage is optimized [87, 92]. A straight percutaneous trial is used for
the insertion of cylindrical leads, which involves maneuvering the lead into the posterior
paramedian epidural space up to the painful location and anchoring the lead to the
interspinal ligaments with nonabsorbable sutures. After the trial period, the trial lead is
replaced by a new lead, which is connected to the IPG. Insertion of paddle-type leads
requires a permanent lead trial, which is a more invasive and risky procedure. A
laminotomy is performed, which partially removes the lamina, so that the electrodes can
be slipped into the epidural space. From there, a percutaneous extension piece is tunneled
from the site of incision out through the skin where it is secured with sutures. If the trial
is successful, the incision is re-opened and this extension piece is cut, and new extensions
are used to connect the leads to the IPG. [38, 87]. The advantage of using paddle-type
leads is that there is less risk of lead migration, where lead movement causes a loss of
paresthesia over the painful region and possible stimulation of other regions, which is a
serious complication associated with spinal cord stimulator implantation and requires
revision surgery [93]. The basic steps involved with the implantation procedure are
shown in Figure 2.2.
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Figure 2.2: Overview of SCS procedure showing where the electrodes and IPG are
placed as well as the basic functions of each component [94]
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Before deciding on SCS as a pain management therapy, the McGill Pain
Questionnaire, Roland Morris Questionnaire, or other methods are used for psychological
screening and pain evaluation. This is to ensure that the patient will actually be amenable
to the therapy, that any prior psychiatric disorders do not interfere with the therapy, and
that the therapy does not aggravate any symptoms of the disorder [87, 95]. Further patient
selection criteria for SCS include unresponsiveness to standard treatments and
inadvisable remedial surgery [95]. In the U.S., the most common indication for use is for
failed back surgery syndrome (FBSS), while peripheral ischemia is the most common
indication in Europe [87, 93]. Contraindications include failed trials with SCS, bleeding
disorders, pacemakers or defibrillators, pregnancy, and severe systemic or local
infections [87].
A summary of various studies involving SCS and its effects on the cardiovascular
system are shown in Table A.2 of Appendix A. These studies were conducted both on
rats and patients with PAOD. The pulse width was constant in all studies at 200 µs while
the frequency was either adjusted to a high setting (~100 Hz) or medium setting (~50
Hz). The treatment duration for rats was significantly shorter (on the order of minutes)
compared to humans (on the order of months). This disparity in treatment duration is
based on acute study design for animals versus permanent implantation in humans. One
advantage to a longer treatment duration is that it allows for analysis of long-term safety
and effectiveness with SCS that cannot as readily be assessed with other neurostimulation
techniques. The electrode array was inserted into the epidural space using the straight
percutaneous method over specific vertebral levels, depending on which limbs were
affected, e.g. the electrodes were placed at the T-10 vertebral level if ischemia was
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present in the legs [32]. Reductions in MAP and vascular resistance as well as increases
in blood flow were observed in these studies [32, 37, 96, 97].
A possible mechanism of action for these hemodynamic changes may be that
SCS causes antidromic activation, i.e. conduction in the opposite direction of both
cutaneous and muscle afferents, which releases vasodilators, such as calcitonin generelated peptide (CGRP), from the dorsal roots (Figure 2.3) [96, 97]. Through a very
similar pathway, prostaglandins, specifically PGE2 , may be released from the
endothelium causing a reduction in sympathetic tone by inhibiting norepinephrine release
from sympathetic nerve terminals [32]. In fact, when indomethacin, a prostaglandin
synthesis inhibitor, was intravenously injected into cats experiencing SCS, vasodilation
was significantly reduced, and in some cases, abolished [98].

Figure 2.3: Possible mechanism of action for SCS-induced hemodynamic changes. High
intensity electrical stimulation in the epidural space activates both Aδ-fibers and C-fibers
in the dorsal root ganglion (DRG), both of which activate extracellular signal-regulated
kinase (ERK) and protein kinase B (AKT) that cause activation of the transient receptor
potential vanilloid receptor-1 (TRPV-1) on these neurons. Activation of TRPV-1 releases
CGRP that causes systemic effects such as release of nitric oxide (NO) from ECs and
SMC relaxation, leading to increased blood flow and decreased vascular resistance [99]
2.3 Electroacupuncture
Traditional acupuncture has been used for over 3000 years. This ancient Chinese
therapy is based on the premise of restoring a blockage in “ch’i” through a careful
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balancing of “yin and yang”. This is accomplished through the application of needles at
specific acupuncture points (acupoints) along the body. Although largely discredited at
first for its metaphysical explanations, such as the idea of manipulating the life energy
“ch’i” that flows through “meridians”, i.e. channel networks within the body, by
stimulating acupoints that run along these meridians, it has become a very popular form
of therapy for chronic pain in the past several decades [100]. In 1975, it was found that
by adding electricity to the needles, the pain modulation was 100% more effective over
traditional needles [101]. Thus, electroacupuncture (EA) was born.
Both traditional acupuncture and EA have now found widespread use in the U.S.
In a National Health Statistics Report, the number of Americans actively using
electroacupuncture as an adjunct treatment for chronic pain was estimated at 3 million
[102]. The rise in popularity for EA mirrors the rise in alternative medicine use in general
over more conventional forms of medicine, part of this owing to its ease of use. Small
alligator-clip electrodes are attached to each needle, each with an associated lead that
plugs into the electrotherapy device. The downside of EA and traditional acupuncture is
that a licensed practitioner must perform the procedure each time. However, there are
newer forms of EA that do not utilize needles and instead use adhesive electrodes very
similar to those used for TENS, which then allows the user to perform the procedure
themselves. Around 30 minutes of continuous stimulation is usually recommended [103].
An example of a typical EA configuration using needles is shown in Figure 2.4.
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Figure 2.4: Set-up of an EA unit on a patient, consisting of electrodes with leads inserted
into a programmable stimulator [104]
Unfortunately, there is not a substantial body of evidence to support the efficacy
of EA as a pain management therapy and the mechanisms of action are still poorly
understood [105-108]. For this reason, EA is not commonly prescribed by physicians for
pain treatment. Nevertheless, it is increasingly being used by the general public, and more
clinical trials are underway to investigate both the mechanisms and potential treatments
for this neurostimulation technique; in fact, there are currently 36 clinical trials involving
EA that are actively recruiting according to the National Institutes of Health (NIH) [109].
Furthermore, when EA is combined with conventional medication, such as prednisone,
the clinical effectiveness is even greater in reducing pain compared to medication alone
[109-111]. Although specific indications for use have not been established yet, EA is
generally used as an analgesic for muscle spasms, neurological disorders, chronic pain,
injuries, and paralysis [107]. The main contraindications include patients with a history of
seizures, heart disease, stroke, or epilepsy, as well as patients with implantable electrical
devices such as pacemakers [103].
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A summary of various studies involving EA and its effects on the cardiovascular
system are shown in Table A.3 of Appendix A. Very few of these studies involved
humans; most used rats and dogs. Very high intensities (~5x above sensory intensity)
were used in all these studies, which appears to be necessary to alter blood flow. Wider
pulse widths (> 250 µs) and lower frequencies (< 20 Hz) were used compared to the
TENS and SCS studies. The electrodes were applied at acupoints specific to the ischemic
area. The effect of electrode placement was commonly investigated in these studies, as
stimulation of different acupoints may cause very different changes within the
cardiovascular system, e.g. stimulation of the hand caused decreased BP and blood flow
while stimulation of the tibial and saphenous nerves caused increased BP and blood flow
[112, 113], although these results may also be attributable to differences in animal and
human hemodynamics.
A possible mechanism of action for these hemodynamic changes may be that EA
decreases or increases sympathetic tone depending on where stimulation is applied. A
decrease in sympathetic tone may result from a similar pathway as presented in Figure
2.3, in which vasodilation occurs from the release of CGRP [68, 114]. Changes in activity
of different brain regions in response to EA may also be responsible for the decrease in
SNS activity, e.g. modulation of RVM neurons responsible for the maintenance of
arterial BP, increased expression of nitric oxide synthase in the hypothalamus, or
activation of nucleus ambiguus (NAmb) neurons responsible for the regulation of
autonomic functions [115] In contrast, an increase in sympathetic tone may result from a
reduction in prostaglandin release [116, 117]; it may also be attributed to increases in
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muscle sympathetic nerve activity (MSNA), which may possibly occur from a
modulatory effect on PAG and arcuate neurons that control BP [115, 118].
2.4 Interferential Current
Interferential Current (IFC) stimulation is a noninvasive neurostimulation
technique that is very similar to TENS in terms of its application and use. It utilizes the
same type of adhesive skin electrodes connected via leads to a stimulator unit. The main
difference with IFC, as compared to TENS, is the frequency used. Alternating-current
(AC) sine waves or square waves at two different carrier frequencies superimpose to
produce an interference, i.e. interferential current, otherwise known as an alternating
modulation frequency (AMF). Typically, one current is held at 4000 Hz while the other is
held at 4100 Hz to produce an AMF of 100 Hz [75]. One advantage of this approach is
that IFC can penetrate into deeper tissues because skin impedance decreases with
increasing frequency, which is important for stimulating both cutaneous and muscle
afferents [75, 119]. The duration of stimulation for IFC is usually around 30 minutes,
similar to that of other neurostimulation techniques [119].
Although more commonly used in other countries, IFC is increasingly used in the
U.S. because of its reported effectiveness and ease of use [71, 120, 121]. However, its use
normally requires oversight by a trained practitioner to ensure that modulation of the
currents is properly performed. An example of how this modulation is accomplished
clinically is shown in Figure 2.5.
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Figure 2.5: Diagram showing how a dual-channel IFC unit can be applied to the skin
surface to produce an AMF and potentially cause pain relief within deep tissue [119]
Most IFC devices tend to be more expensive and less portable than TENS devices,
making their widespread use further limited [119]. More portable units have been
developed recently, including multi-functional units capable of both IFC and TENS,
making this intervention more cost-effective [75]. IFC is indicated for use in chronic
pain, post-traumatic pain, and post-surgical pain. However, the clinical use of IFC over
TENS has come into question, as some studies have shown that it is no more effective at
relieving pain than TENS [122, 123]. The contraindications for IFC include undiagnosed
pain, infections or inflammation in the stimulation region, patients with implanted
pacemakers or defibrillators, and patients who have a history of epilepsy [75].
A summary of various studies involving IFC and its effects on the cardiovascular
system are shown in Table A.4 of Appendix A. All these studies were conducted on
healthy human subjects. In all cases, the intensity level was adjusted to sensory intensity
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with an average pulse width of 160 µs, frequency of 100 Hz, and treatment duration of 20
minutes. The electrodes were applied on specific dermatomes e.g. C7 and T4, the thigh,
or the forearm. Reductions in MAP, CVR, and ischemic pain, as well as increases in CBF
were witnessed in these studies [124-126].
A possible mechanism of action for these hemodynamic changes may be that IFC
inhibits SNS activity and causes local vasodilation based on very similar mechanisms as
discussed in Section 2.1 involving TENS. Whether the inhibition in SNS activity and
local vasodilation is more pronounced with IFC compared to TENS is still to be
determined, but it seems likely that this would be the case, since IFC stimulates deeper
muscle afferents in addition to cutaneous afferents [119]. This idea will be further
explored in Chapters 4 and 5.
In all these neurostimulation studies, perfusion was measured in a variety of ways
including laser Doppler flowmetry, laser speckle contrast analysis, venous occlusion
plethysmography, and photoplethysmography, among others. The accurate interpretation
of perfusion is crucial to fully understanding the mechanisms underlying hemodynamic
responses to neurostimulation. This interpretation can be biased by a number of factors,
such as motion artifact caused by movement of the subject or the connecting cables,
calibration method (every manufacturer calibrates the equipment differently),
temperature fluctuations, and inherent differences in the way each system measures
perfusion. For example, laser speckle contrast analysis uses spatial averaging when
scanning over a tissue region, which leads to a loss of resolution and an underestimation
of the actual perfusion within this region [127]. Commonly used perfusion measurement
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systems will be discussed in Chapter 3, including each system’s inherent advantages and
disadvantages.
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CHAPTER 3 – PERFUSION MEASUREMENT INSTRUMENTATION
3.1 Justification for Non-invasive Measurements of Perfusion
Before discussing the theory and practical use of these perfusion measurement
systems, the reasoning for why noninvasive perfusion systems are capable of providing
accurate measures of both cutaneous and muscle blood flow will be explained. During a
resting state, partition of blood flow to the muscle and skin is nearly equivalent with a
slightly higher percentage of blood flow in the muscle. In a diseased state, such as CHF,
blood flow in both vascular beds is reduced compared to healthy subjects. During
exercise, both cutaneous and muscle blood flow decrease in non-active vascular beds and
increase in active vascular beds [128]. A change in skin temperature can also be
correlated with changes in cutaneous blood flow, since heat is a by-product of cellular
metabolism [129]. Based on these correlations between cutaneous and muscle blood
flow, measurements of cutaneous blood flow using noninvasive methods, such as laser
Doppler flowmetry (LDF), can be used to estimate muscle blood flow, and perfusion in
other vascular beds such as coronary and renal. This has important applications in the
diagnosis and treatment of cardiovascular diseases. For example, cutaneous
microangiopathy is associated with diabetic retinopathy and renal microvascular disease,
in which cutaneous blood flow decreases as a function of the severity of the disease
[130]. Cutaneous microcirculatory dysfunction has also been implicated in CAD patients
who exhibit impaired post-ischemic capillary perfusion, i.e. reactive hyperemia, but
normal perfusion during resting conditions [131]. This is in accordance with PAOD
patients who also exhibit impaired reactive hyperemia [132]. Most importantly,
noninvasive measurements of perfusion can provide relative measures of ischemia and
reperfusion, which correlate well with more traditional, invasive measurements of
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perfusion, such as the hydrogen clearance, Xenon clearance, fluorescent dye studies, and
photoplethysmography [133, 134]. For the pre-pilot work (Chapter 5) and eventual pilot
study (Chapter 4), LDF was chosen to measure cutaneous blood flow, because of its high
sensitivity to local microcirculatory changes, ability for continuous, real-time
measurements, noninvasiveness, and ease of use.
3.2 Laser Doppler Flowmetry
Laser Doppler flowmetry (LDF) was developed in 1984, when Allan Holloway
unveiled the first noninvasive blood perfusion monitoring system capable of continuous,
real-time measurements. Utilizing a Helium-Neon laser source and an optical fiber, light
is transmitted at 632.8 nm from the system to the skin. Depending on the particular probe
configuration, a penetration depth of 1 – 1.5 mm is possible. The light that is transmitted
to the skin is reflected back to a photodetector through “receiving” optical fibers. For
nonmoving components within the skin, this light is reflected back at the same frequency
as the incident source. For moving components, such as red blood cells (RBCs), the light
is Doppler shifted or scattered, such that the frequency changes when it hits the
photodetector. This frequency shift or beat frequency is directly proportional to the
velocity of the RBCs or other moving components, i.e. higher velocities cause greater
frequency shifts compared to the incident frequency [127, 135]. A diagram of this
phenomenon is shown in Figure 3.1. The measured output of LDF systems is in flux,
measured in perfusion units (PU), which is calculated as such:
𝐹𝑙𝑢𝑥 = 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑅𝐵𝐶𝑠 𝑚𝑜𝑣𝑖𝑛𝑔 𝑖𝑛 𝑡ℎ𝑒 𝑡𝑖𝑠𝑠𝑢𝑒 𝑠𝑎𝑚𝑝𝑙𝑖𝑛𝑔 𝑣𝑜𝑙𝑢𝑚𝑒 × 𝑅𝐵𝐶 𝑚𝑒𝑎𝑛 𝑣𝑒𝑙𝑜𝑐𝑖𝑡𝑦
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Figure 3.1: Light from the incident source impinges on both non-moving components
within the tissue and from RBCs, which is then reflected back to a photodetector and
processed [136]
Within the practice of LDF, laser Doppler perfusion monitoring (LDPM) and
laser Doppler perfusion imaging (LDPI) systems are used. LDPM systems measure
perfusion within a very small region or point, usually the equivalent of 1 mm3 in terms of
tissue volume, which may vary based on site of observation and concentration of RBCs at
the time of measurement [136]. LDPI systems measure perfusion in much larger areas,
upwards of 1000 cm2 [137]. The larger spatial field of view is accomplished via a
complementary metal-oxide semiconductor (CMOS) camera (Figure 3.2). In this case,
the reflected or backscattered light from the tissue is focused onto a detector array within
the camera. Each pixel in the array is used to calculate a perfusion value for that specific
pixel dimension within the tissue. With these CMOS cameras, the entire image is
illuminated and acquired simultaneously. Average perfusion values can then be
calculated for specific regions within the field of view using specially designed software.
This is a distinct advantage over earlier versions of the LDPI systems, which scanned the
area point by point, making the whole process take significantly longer [127]. Both
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LDPM and LDPI systems have been used in a variety of applications including burn and
wound assessment, quantification of microcirculatory disorders, amputation level
determination, and dentistry, among others [127, 136, 137]. LDPM tends to be more
useful in quantifying temporal changes within cutaneous vasculature, such as during
vascular occlusion tests or in response to electrical stimulation [138]. LDPI serves better
as a clinical diagnostic tool, e.g. ulcer or diabetic microangiopathy assessments [127]. An
example of a blood perfusion map using LDPI in the case of induced ischemia is shown
in Figure 3.3.

Figure 3.2: Equipment set-up for a typical LDPI system [139]
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Figure 3.3: Blood perfusion map using LDPI on the hand; participant subjected to a
vascular occlusion test to simulate ischemia; perfusion scale bar shown on right [137]
Although LDF is being used more often in research and clinical settings, as
indicated in Figure 3.4, there are still a number of drawbacks that limit its widespread
use and applicability. For one, there is significant inter-individual variability in the
measurements obtained, because of differing hematocrit levels and physiological states of
each subject, as well as variability introduced by several environmental factors including
ambient temperature and humidity. Absolute calibration of the LDF system is difficult
and each manufacturer tends to go about it in a different way. The variability in both
calibration and among individuals make standardization and repeatability problematic
[127]. Probe placement with LDPM systems is subjective, considering that the volume of
tissue that is measured is very small and most tissue types exhibit heterogenous blood
flow, even within the same relative location. This usually prevents comparison of results
to other studies [140]. However, microvascular reactivity, such as in the case of occlusion
tests, can be compared readily to other studies by calculating a percentage change from
an initial baseline value [141]. Even with newer CMOS cameras, LDPI systems aren’t
fast enough to capture the frequency content of the Doppler signal in its entirety. A
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normal Doppler power spectrum has frequency components up to 15 kHz, so the
sampling frequency of the LDPI system must be at least double that [127]; even with
some of the newest systems on the market today, this sampling frequency is still not yet
achievable [137, 142]. This lower sampling frequency tends to lead to underestimation of
the actual perfusion values [127]. In more recent years, there have been concerted efforts
to create internationally standardized protocols for data recording and for various
diagnoses, making the LDF method a more useful and reliable tool for monitoring the
microcirculation [143].

Figure 3.4: The number of publications utilizing the LDF method, either LDPM or LDPI,
from 1980 through 2006 [144]
3.3 Laser Speckle Contrast Analysis
Laser speckle contrast analysis (LASCA), otherwise known as laser speckle
contrast imaging (LSCI) or simply laser speckle imaging (LSI), utilizes very similar
methodology as LDF in measuring microcirculation. “Laser speckle” is an interference
44

pattern produced from light beams of the same frequency. This is in contrast to LDF
where the superimposed waves have different frequencies. However, in both cases,
identical equations are used to correlate the random fluctuations caused by changes in
optical path lengths of the light beams to the velocity distribution of the moving
components, i.e. RBCs within a given tissue. If the object is static, no change in optical
path length will occur, and thus the speckle pattern will remain stationary. To scan a
given area, a set-up very similar to Figure 3.2 for an LDPI system is typically used. A
number of parameters can be manipulated with the resulting contrast map including the
exposure time, number of pixels, scaling, and color coding. The number of pixels is
important, because with too few pixels, proper statistical analysis cannot be performed to
analyze the image, and with too many pixels, the spatial resolution is significantly
diminished [127].
LASCA was originally only used for measuring perfusion in the skin, but has now
become extremely important for monitoring cerebral blood flow [127, 145-147]. The
increase in use for LASCA is partially because it has quicker response times than LDPI,
which helps to improve patient comfort since they must remain perfectly still during the
scan [148]. The LASCA method is capable of near real-time imaging (capture and
processing takes less than a second on average), which is important when evaluating
mechanical or pharmacological interventions on the microcirculation. However, LASCA,
unlike LDF methods, does not measure the frequency spectrum; it only measures the
velocity distribution. Therefore, only an average velocity of RBCs can be obtained rather
than flux, i.e. perfusion. Furthermore, the velocity distribution within a given tissue must
be assumed to use the equations associated with this technique [149]. The most
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significant disadvantage is the loss of resolution caused by the spatial averaging used in
the analysis [127]. However, more recent developments in LASCA technology and the
algorithms used have ameliorated many of these disadvantages and made this technique
more comparable to LDPI [127, 140, 148].
3.4 High Frequency Ultrasound
Ultrasound has been around since the late 1940s, when it was first used in sonar
technology during World War II. Then, in 1955, Shigeo Satomura and Yasuhara Nimura
developed the first Doppler ultrasound device, specifically for monitoring blood flow. It
is now commonly utilized as a diagnostic imaging modality in medicine [150].
Ultrasound, as the term implies, is a sound wave that can be affected by properties of the
medium such as density, as well as environmental factors such as temperature. However,
it has a much higher frequency (> 20 kHz) than normal sound waves, but still behaves
like a wave in that it transmits energy from one source to another. In ultrasound imaging
systems, ultrasonic waves from a transducer propagate through a tissue and interact with
mechanical discontinuities, e.g. planar interfaces between the skull and brain or between
fat and liver. An echo is created from this interaction, which is a reflection or scattering
of the original ultrasonic wave; ultrasonic images are then formed from these echoes
[127, 150]. The acoustic impedance of the ultrasound system is the primary factor that
determines the amplitude of a given echo. As an example, blood vessels are mainly
composed of connective tissue, and connective tissue exhibits impedance; thus, blood
vessels tend to be more “echogenic”, i.e. reflect more of the sound waves because of their
higher acoustic impedance [150]. In terms of measuring blood flow, the Doppler effect is
utilized in the exact same manner as with LDF. Moving components, such as RBCs,

46

scatter the ultrasonic wave, which leads to a shift in frequency of the reflected waves, and
this frequency shift is directly proportional to the velocity of the moving components.
Although ultrasound has been used to monitor blood flow for decades, it wasn’t
until the early 2000s that the microcirculation could be properly imaged. The reason for
this was the limitation in imaging frequency and resolution. Before this time, maximum
imaging frequencies were between 12 – 15 MHz with a resolution of about 300 µm. With
the development of micro-ultrasound, imaging frequencies are now in the 15 – 80 MHz
range with resolutions in the 40 – 200 µm range [127]. The output of these systems can
be displayed in a number of ways including pulsed Doppler, color Doppler, and power
Doppler. Pulsed Doppler measures blood velocity with respect to time at one point in
space, so it outputs the hemodynamics of that location. If vessel cross-sectional area can
be determined, then flow rate in milliliters per minute can be calculated. Color Doppler
presents a cover overlay of mean RBC velocity on top of a grayscale image of the
anatomy, and can be used to distinguish arterial versus venous blood flow (Figure 3.5).
However, it is only capable of providing relative flow velocities, unlike pulsed Doppler.
Power Doppler computes the integral of the Doppler power spectrum, which is a
representation of relative blood volume, assuming constant hematocrit. Therefore, it can
provide a morphological image of the microvasculature in the region of interest (ROI).
Vessels that are smaller than 50 µm cannot usually be detected by power Doppler, and
this modality is more prone to motion artifact than the others [151].
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Figure 3.5: Color Doppler image of the brain cortex showing blood flow away from the
transducer in blue and blood flow toward the transducer in red [151]
3.5 Other Instrumentation
A full review of current microcirculation monitoring techniques is beyond the
scope of this work and a more comprehensive and detailed review can be found in
Microcirculation Imaging by M.J. Leahy [127]. A brief description of some of these
other imaging modalities will be discussed here. These include photoplethysmography
(PPG), nuclear magnetic resonance imaging (NMRI), and micro-positron emission
tomography (micro-PET).
PPG has been used to measure skin blood flow since the late 1940s. It utilizes
electromagnetic radiation, which is transmitted from an infrared light-emitting diode
(LED) source to the skin. The backscatter is measured in terms of hemoglobin absorption
by a phototransistor, which indicates the relative volume of blood in the ROI. After signal
processing, the output is displayed on a chart recorder. The measurement depth is around
1 – 1.5 mm for most probes, which are noninvasive like the LDPM probes. PPG is used
in the assessment of skin ulcers and flap viability, in the evaluation of PAOD and CVD,
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and in measuring the pharmacodynamic response of various drugs on the circulation
[135].
NMRI is capable of quantifying blood flow within the entire size range of the
vasculature, i.e. large diameter arteries and small diameter capillaries. This is
accomplished either through arterial spin labeling (ASL) or dynamic susceptibility
contrast (DSC). ASL uses magnetically-‘labeled’ water protons that function as a tracer,
which is similar to other imaging modalities such as single-photon emission computed
tomography (SPECT), PET, and CT, except that there is no injection of a contrast agent;
it instead labels the “blood magnetization”. DSC uses an injection of a contrast agent
called Gadolinium (Gd) encapsulated in a chelate molecule for dynamic imaging.
Although DSC is a more clinically viable option in terms of high signal-to-noise ratios
and simple acquisition procedures, ASL is completely non-invasive, can be operatorindependent, and is intrinsically more quantitative; hence its popularity in research and
the clinical setting is increasing [152]. In ASL, blood flow causes a shift in magnetization
that is displayed on the resulting image, which is subtracted from a “control” image
where there is no magnetization [127]. There are numerous ways of labeling this
magnetization, most commonly continuous or pulsed ASL is used, as well as numerous
ways of acquiring the image signal and quantifying the blood flow. However, recently the
ASL Network was established to assimilate the many different procedures and theories
used in this technique in the hopes of increasing its clinical utility [152].
PET systems have been in use since the 1960s and have served as a powerful
clinical diagnostic tool in terms of noninvasively studying human physiology and
biochemistry. Starting in the 1990s, PET systems were scaled down to produce
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resolutions of around 2 mm, which is when the term micro-PET became popular. MicroPET uses a radioactive substance that decays by positron emission when it collides with
an electron. This annihilation causes high-energy photons to be emitted, which are
collected by the micro-PET detectors. By collecting a multitude of photon pairs, a
topographic image is created. This technique has the advantages of being very sensitive,
having high signal-to-noise ratios, and having the capability of imaging any type of target
from metabolic substrates to nanoparticles. Thus, absolute measurements of blood flow
are possible [127]. However, it is still limited in terms of its spatial resolution because of
the finite distance that the positron can travel in any given tissue before collision. In
addition, many of the radioisotopes used in perfusion monitoring have short half-lives,
although newer agents such as [11 C]DMDPA have helped mitigate this pitfall [153]. The
combination of micro-PET with micro-computed tomography (micro-CT) scanners has
vastly improved the spatial resolution as well; this type of dual modality imaging system
is shown in Figure 3.6.

Figure 3.6: Siemens Inveon Micro-CT/PET system capable of ultra-high resolutions
down to 15 µm [154]
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CHAPTER 4 – CLINICAL PILOT STUDY DESIGN
4.1 Justification for the Use of TENS
The use of TENS for the pilot study was chosen because of its low cost, wellestablished parameters for safe and effective use, and its favorable impact on
hemodynamics and pain reduction in humans. Since this was a pilot study in healthy
subjects, SCS was not chosen due to its invasiveness. EA and TENS have similar effects
on cutaneous blood flow and skin temperature in the hand [65]. However, EA use is
limited by the need for a licensed acupuncturist to properly place the electrodes at the
correct acupoints. In addition, most of the research involving EA has been conducted on
animals, and with mixed results [64, 68, 113, 155]. For the pilot study, we compared our
results to other healthy, human subject studies using similar protocols with TENS. There
is no difference between TENS and IFC in terms of treating chronic back pain, but both
are still more effective than no treatment, i.e. both treatments caused reductions in the
Visual Analog Scale (VAS) and Roland-Morris Disability Questionnaire (RMDQ) with
regards to pain intensity, consumption of pain medications, and disability [70]. Even with
ischemia- induced pain, both techniques are nearly equivalent in their analgesic effects
when comparing reductions in pain intensity using the VAS and McGill Pain
Questionnaire (MPQ) [119]. As far as we know, there have been no direct comparisons of
the effect of IFC and TENS on the cardiovascular system, although separate studies of
IFC and TENS using almost identical protocols have been conducted, but the authors
only mentioned that similar results were obtained, i.e. reductions in MAP and calf
vascular resistance with simultaneous increases in calf blood flow [81, 126]. One of the
goals of this study was to investigate these two neurostimulation techniques and
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determine which elicited greater hemodynamic changes, which will be discussed in more
detail in Chapter 5.
4.2 Mechanism of Action of TENS on Hemodynamics
The gate control theory has been used for decades to explain how
neurostimulation effectively mitigates pain, but it has not been used to explain the
changes that are witnessed within the cardiovascular system, i.e. increased blood flow,
decreased blood pressure (BP), and decreased vascular resistance. Specifically, TENS
seems to modulate the gate control system by stimulating large diameter, Aβ-fibers and
Group I – II muscle afferents, causing an increased inhibitory effect of GABA on NS and
WDR neurons. This effectively reduces the transmission of pain signals carried by small
diameter, C-fibers and Group III – IV muscle afferents to the dorsal horn neurons. Thus,
the original noxious stimulus still reaches the brain, but the painful sensation and
response that occurs is reduced [47, 156, 157].
Simultaneous to the reduced pain sensation, the metaboreflex may be reduced.
Normally, the metaboreflex (muscle chemoreflex) is triggered by ischemic by-products,
e.g. lactic acid, hydrogen ions, adenosine, prostaglandins, bradykinin, and potassium,
with potassium being the most potent stimulator of intramuscular chemoreceptors located
on group III – IV muscle afferents [158-161]. The metaboreflex causes an increase in
sympathetic activity, which in turn increases cardiac output (higher HR and SV) and
vasoconstriction in nonactive tissues [162]. At the same time, there is a blunted
vasoconstrictive effect on active tissues (due to functional sympatholysis), leading to a
net increase in blood flow and oxygen to these tissues [163]. Although this process is
imperative in healthy individuals to redistribute blood flow to active tissues during
exercise, it can actually worsen the symptoms in PAOD patients who have increased
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reactive oxygen species (ROS) production as a result of the disease, which also stimulates
Group IV muscle afferents, [164, 165]. This is evidenced by greater changes in MAP in
response to exercise and more sympathetic activation, which is related to disease severity,
i.e. the more severe the disease state, the greater the metaboreflex activation will be and
the more sympathetic activation that will occur [165]. Thus, there is likely to be a more
pronounced effect when TENS is used on PAOD patients compared to on healthy
individuals. Specifically, it should reduce BP but should not affect HR substantially,
because TENS at sensory intensity does not affect descending control mechanisms from
the brain, and it is these central mechanisms that influence HR [156, 166]. Furthermore,
the effect of TENS on HR has produced inconclusive results [33, 67, 81].
The reduction in the metaboreflex, in theory, should not cause local vasodilation,
yet in many studies, an increase in blood flow still occurs with application of TENS [33,
36, 66, 167]. Therefore, an additional mechanism must be at work to explain this local
vasodilatory effect. A few studies have investigated how catecholamine metabolism
increases in response to TENS and the findings suggest that it may be inhib iting
norepinephrine (NE) release [33, 36, 79, 168]. This inhibition of NE release may occur if
TENS causes serotonin release. As stated in Section 2.1, high frequency (> 50 Hz) TENS
activates δ-opioid receptors and low frequency TENS (< 10 Hz) activates µ-opioid
receptors in the RVM and the spinal cord [69, 169]. This activation may occur through
release of β-endorphins that selectively bind to µ-opioid receptors [170] or the release of
enkephalins that selectively bind to δ-opioid receptors [171]. A complex presynaptic
synergistic interaction between opioid receptors and serotonin (5-HT) receptors is
responsible for some of the anti-nociceptive effects of electrical stimulation, possibly
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through a decrease in GABA release in spinal interneurons, although this is not fully
understood [172, 173]. TENS stimulates release of serotonin from the raphe nuclei into
the spinal cord, which then activates 5-HT1 , 5-HT2 , and 5-HT3 receptors [174, 175].
Serotonin can either have a depressor effect if neurogenic vasoconstriction is present, as
in the case of PAOD patients, or can have a pressor effect if neurogenic vasoconstriction
is absent [176]. In the case of this depressor effect, presynaptic inhibition of NE from
sympathetic nerve terminals occurs [177]. Normally, electrical stimulation, such as
TENS, stimulates a vasoconstrictor response through the release of NE and ATP from
postganglionic sympathetic neurons [178, 179]. NE activates α2 adrenergic receptors,
which are part of a larger class of adrenergic receptors that mediate smooth muscle
contraction, i.e. vasoconstriction. The α2 receptors exist on SMCs, sympathetic nerve
terminals, peripheral nerve terminals of primary afferent neurons, around injured
peripheral nerves, the dorsal horn of the spinal cord, central terminals of primary afferent
neurons, and in the RVM, locus coeruleus, and other brain regions [180]. They are also
the only adrenergic receptors that are associated with presynaptic inhibition, specifically
of NE, and provide negative feedback to stimulated NE release. Depolarization-induced
release of neurotransmitters, such as NE, from nerves is dependent on the influx of
calcium through voltage-gated calcium channels. N-type calcium channels, which are
coupled to α2 receptors via G-proteins, mediate calcium influx responsible for
norepinephrine release. Serotonin decreases the calcium current through the channels. As
a result, cytosolic levels of calcium decrease, causing inhibition of NE release from the
sympathetic nerve terminal [177, 181]. In addition, both serotonin and activation of α2
receptors have both been implicated in presynaptic and postsynaptic inhibition on
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nociceptive afferents and dorsal horn neurons, resulting in analgesia [182, 183].
Supporting this idea, TENS-induced analgesia was reduced in mice with dysfunctional
α2A receptors, i.e. the hypotensive action of these receptors was completely ablated, but
not in mice with deleted α2C receptors [79]. In this same study, spinal and supraspinal
blockade of α2 receptors in wild-type (WT) mice did not affect the antihyperalgesia of
TENS, while blockade of α2 receptors at the site of application of TENS reduced the antihyperalgesia. In addition, α2A receptors are expressed more on primary afferent neurons
than α2C receptors, suggesting that α2A receptors are mainly responsible for the antihyperalgesic effects. In this case, reductions in pain intensity, metaboreflex activation,
and vasoconstriction could all occur through electrical stimulation of both cutaneous and
muscle afferents.
Although this explanation for TENS-induced vasodilation and subsequent
increases in blood flow seems plausible, other possible receptors, paracrine factors, and
hormones may play some role. For example, TENS-induced vasodilation may result from
activation of β-adrenergic receptors and/or release of acetylcholine, histamine, adenosine,
dopamine, prostaglandins or plasma kinins; however, antagonists for all of these
vasodilators still do not reduce the vasodilatory effect of TENS [184]. TENS does
stimulate release of nitric oxide (NO) from the pedal ganglia of blue mussels (Mytilus
edulis) by activating opioid receptors, as opioid receptor blockade with naloxone
prevented NO release [185]. However, NO does not seem to be responsible for the
induced vasodilation in humans as only the analgesic effects of TENS were blocked with
naloxone [186]. Upregulation, i.e. higher mRNA and protein levels, of CGRP, which is
the most potent of the vasodilators in the DRG, in response to TENS is another
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possibility for the induced vasodilation; this would further stimulate NO release from the
endothelium and cause SMC relaxation [187, 188]. Lastly, TENS increases plasma levels
of vasoactive intestinal polypeptide (VIP), another potent vasodilator, within the
circulation, which the authors believed may be a secondary action attributable to a
decrease in sympathetic activity, possibly as a result of the serotonergic pathway
discussed earlier [189]. Evidence of TENS-induced vasodilation from any other possible
mechanisms is currently unknown.
Multiple mechanisms may underlie the hemodynamic changes induced by TENS,
but it seems that a dual, synergistic mechanism is most likely responsible for these
changes, as shown in Figure 4.1. Specifically, stimulating the Aβ cutaneous afferents and
Group I and II muscle afferents not only closes the “gate” and reduces noxious stimulus
transmission as previously thought, but also reduces the metaboreflex causing a decrease
in SNS activity. In addition, TENS stimulates release of serotonin that inhibits NE release
from sympathetic nerve terminals causing vasodilation. Through this cascade of neural
events, the end result is a reduction in MAP with a simultaneous increase in local blood
flow.
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Figure 4.1: Diagram of the proposed mechanisms for TENS-induced changes on the
cardiovascular system in PAOD patients, involving a reduction in the metaboreflex and
presynaptic inhibition of NE from sympathetic neurons. GABA: Gamma-aminobutryic
Acid; MAP: Mean Arterial Pressure; ROS: Reactive Oxygen Species; NE:
Norepinephrine
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This proposed dual mechanism of action for application of TENS on PAOD
patients should also apply to healthy individuals who experience induced ischemia. In
healthy participants, i.e. no past or current history of any cardiovascular, musculoskeletal,
or neural conditions, who experienced induced ischemia through the inflation of a blood
pressure cuff wrapped around their forearm, MAP and vascular resistance decreased,
while blood flow increased with TENS applied on the C7 and T4 dermatomes; this effect
on the hemodynamics was more pronounced in younger individuals (25 ± 1.3 years of
age) [81]. This may be surprising considering that plasma levels of NE are higher in older
individuals [190, 191], and there is greater endothelial dysfunction and increased
sympathetic tone [192, 193]; TENS has a greater effect when increased SNS activity is
present, such as during isometic exercise [80]. However, the metaboreflex may be
attenuated by age, and with reduced metaboreflex activation, the effect of TENS on SNS
activity will also be reduced [194]. Specifically, sympathetic reactivity to isometric hand
exercise is reduced in older individuals, meaning there is a smaller percentage increase in
sympathetic tone with exercise as compared to young individuals [195]. This could be
explained by the increase in oxidative fibers in skeletal muscle with age, which could
attenuate BP and muscle sympathetic nerve activity (MSNA), i.e. less of a change with
exercise, since glycolytic fibers exhibit a greater exercise reflex response [196]. For
example, in mice, there is a change in muscle myosin heavy chain (MHC) isoforms from
fast, glycolytic Type II fibers to slower, oxidative Type I fibers [197]. Since glycolytic
muscle evokes greater metaboreflex activation than oxidative muscle [196], and if there
is a slow transformation of muscle fibers to a more oxidative phenotype with age [195],
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then it seems reasonable that younger individuals would experience a greater effect from
TENS on the metaboreflex.
Although application of TENS may have a favorable impact on PAOD patients,
the same may not be true of patients with other forms of cardiovascular disease, such as
congestive heart failure (CHF) and hypertensive patients. In CHF patients, the
metaboreflex is reduced, which is evidenced by a blunted increase in systolic blood
pressure (SBP) and calf vascular resistance in the non-exercised limb [161]. This may be
due to impaired left ventricular contractility, which limits cardiac output (CO). In this
case, heart rate (HR) would increase, but stroke volume (SV) would decrease, so CO
would not increase as much during exercise. The SV decrease is related to impaired
contractility and increased ventricular afterload sensitivity, whereby the ventricles
become more sensitive to pressure changes [198, 199]. An attenuation of the
metaboreflex has also been found in hypertensive patients [200]. Thus, the effect of
TENS may not only depend on the age of the individual, but also if that individual
exhibits different forms of cardiovascular disease.
4.3 Pilot Study Design
To test the proposed mechanisms of TENS and its effects on hemodynamics, a
pilot study will be performed after some pre-pilot work is conducted to optimize the
study design, which will be discussed in Chapter 5; what follows is an “expected” study
design based on a pre-approved protocol submitted to the Institutional Review Board
(IRB) at Cal Poly.
For this pilot study, young, healthy, college-aged students between the ages of 18
and 24 will be recruited through department emails, fliers, and “word of mouth”.
Volunteers will complete an informed consent document (Appendix B) and a short
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medical history questionnaire to ensure that they do not present any of the
contraindications for TENS and are free of any symptoms or signs of cardiovascular
disease (Appendix C). In qualifying subjects, C7 and T4 dermatomes on the back will be
stimulated; these dermatomes innervate the arms and hands as well as the thoracic region
over the pectorals (Figure 4.2).

Figure 4.2: Dermatomes for the various regions of the human body [201]
TENS will be applied to these dermatomes to investigate its effectiveness in increasing
blood flow to the limb, decreasing BP, and reducing ischemic pain, using previously
established parameters for frequency, pulse duration, treatment duration, and intensity

60

[33, 36, 63, 67, 80, 81]. Ischemic pain in the forearm will be induced with a blood
pressure cuff [81, 119, 192]. CBF will be measured with a non-invasive laser Doppler
flow system (moorVMS-LDF2), BP and HR will be measured with a digital blood
pressure monitor (Life Source UA-767 Plus), and pain intensity will be measured using
the Numerical Pain Rating Scale (NPRS) (Appendix D).
During one of the two treatment days, the participant will undergo the postexercise without circulatory occlusion (PECO-) protocol. On the other treatment day, the
post-exercise with circulatory occlusion (PECO+) protocol will be followed. Therefore,
all participants will undergo all treatment conditions. The order of these protocols will be
randomized for each participant using a given code on the medical history form. The first
15 minutes will be allocated either to the placebo condition or TENS condition, a 30minute break will be given, and then 15 minutes will be allocated to the other condition
(Figure 4.3). Thus, the order of placebo and treatment conditions will also be
randomized. During the placebo condition, subjects will have the electrodes attached to
the upper back just as during the treatment condition, but no current will be applied from
the TENS unit.

61

Eligible
participants
Treatment

Treatment

Day 1

Day 2

PECO -

PECO +

Placebo

TENS

Placebo

TENS

30-minute
break

30-minute
break

30-minute
break

30-minute
break

TENS

Placebo

TENS

Placebo

Figure 4.3: Study flow diagram for the pilot study
We hypothesize that ischemia-induced individuals who receive TENS will exhibit
an increase in cutaneous blood flow (CBF) and decreases in cutaneous vascular resistance
(CVR), BP, and pain intensity compared to those who do not receive TENS.
Furthermore, the application of TENS will cause a greater decrease in BP in ischemiainduced individuals compared to non-ischemia-induced individuals; CVR and CBF
responses in non-ischemia- induced individuals with TENS will be more pronounced than
in those same individuals who do not receive TENS, i.e. CVR will decrease and CBF will
increase. Table 4.1 shows these expected changes for the control and treatment with
TENS groups with and without post-exercise circulatory occlusion (PECO).
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Table 4.1: Expected Outcomes for Systemic Hemodynamic Parameters and Pain Intensity
for both Control and TENS Groups with and without PECO*

Heart Rate
Blood Pressure
Blood Flow
Vascular Resistance
Pain Intensity

Control
PECOPECO+
↓
↓
↑
↓
↓
-

* PECO+

TENS
PECOPECO+
↓
↓
↓↓
↑↑
↑
↓↓
↓↓
↓
↓↓

= Post-exercise with Circulatory Occlusion; PECO- = Post-exercise without Circulatory
Occlusion; Arrows indicate change from baseline reading
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CHAPTER 5 – PRE-PILOT WORK
5.1 Methods
To optimize the future pilot study design, comparison studies between IFC and
TENS, and two different areas of application (forearm and back) were investigated to
determine which combinations produced the greatest hemodynamic changes. These
studies were run over the course of three weeks on both myself and my partner in this
project. The protocol, as described in Appendix E, was followed, except for the
following deviations: there was only a 10 minute break in between sessions instead of 30,
pain was assessed every 3 minutes instead of every minute, blood flow was measured in
the left palm and anterior brachial region of the left arm instead of in the left and right
palms, and the control condition always preceded the TENS or IFC condition instead of
being randomized. Ischemia was induced using a manual blood pressure cuff (CVS
Pharmacy Model #BPAG1-20CVS) wrapped around the subject’s left forearm. Isometric
exercise was performed using a hand dynamometer. Electrical stimulation was provided
by an InTENSity Select Combo TENS/IF/MIC/EMS Stimulator. CBF and skin
temperature were monitored using a Moor Instruments VMS-LDF2 and VP1T/7 skin
probes attached just distal to the elbow and wrist creases. BP and HR were assessed
halfway through each treatment interval, i.e. baseline, occlusion, exercise, and recovery,
using a Life Source digital blood pressure monitor (Model #UA-767 Plus) with the cuff
wrapped around the subject’s right arm. MAP was calculated from the equation:
𝑀𝐴𝑃 =

2
1
𝐷𝐵𝑃 + 𝑆𝐵𝑃
3
3

and CVR was calculated from the equation:
𝐶𝑉𝑅 =
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𝑀𝐴𝑃
𝐶𝐵𝐹

Respiration was monitored using a Pneumotrace II respiratory belt (ADInstruments,
Model #MLT1132/D). If the raw breath signal exceeded ±50 mV during anytime period,
causing motion artifact in the blood flow recordings, then the data was deleted over that
interval. Any additional motion artifacts were also removed from the data trace. All
measurements, besides BP, were continuously monitored using a PowerLab 26T system
(Model #ML4856) and LabChart 7 Pro software. The output of such measurements in
LabChart is shown in Figure 5.1, the entire experimental set-up is shown in Figure 5.2,
the different treatment parameters, i.e. frequency, pulse width, treatment duration, and
intensity, are shown in Table 5.1, and electrode placement for both IFC and TENS on the
forearm and back is shown in Figure 5.3.

Figure 5.1: Representative data trace showing the raw breath signal in mV, the
respiratory rate in BPM, the grip force in N, and the blood flow measurements at the two
different locations in PU
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Figure 5.2: Experimental set-up for pre-pilot work A) Manual blood pressure cuff B)
Hand dynamometer C) Digital blood pressure cuff D) Respiration belt E) LDF system F)
PowerLab system G) Blood pressure monitor H) Stimulator I) Laptop with LabChart
software
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Table 5.1: Treatment Parameters for TENS and IFC Testing *
Treatment
Method

Frequency (Hz)

Pulse Width (µs) Treatment
Duration (min)

Intensity Range
(mA)

TENS on Back at
High Frequency

100

200

15

12-13

TENS on
Forearm at High
Frequency

100

200

15

6-8

TENS on Back at
Low Frequency

4

200

15

11-14

TENS on
Forearm at Low
Frequency

4

200

15

6-8

IFC on Back at
High Frequency

100 (modulated) 200

15

7-11

IFC on Forearm
at High
Frequency

100 (modulated) 200

15

5

* Intensity for

each subject was individually adjusted to the point just below motor threshold i.e. no visible
muscle contraction or sensations of pain
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Figure 5.3: Electrode placement for: IFC on the forearm (upper left), TENS on the
forearm (upper right), IFC on the back (lower left), and TENS on the back (lower right);
1) Channel 1 of the stimulator 2) Channel 2 of the stimulator
The hypothesis for all the treatment conditions was that stimulation would cause
an increase in CBF with a concomitant decrease in BP, CVR, and pain intensity.
Furthermore, it was expected that application of IFC on the back and on the forearm
would produce greater favorable changes in these endpoints compared to TENS, because
of its ability to stimulate deeper tissue, i.e. more muscle afferents. It was also expected
that high frequency TENS would be more effective than low frequency TENS, because
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high frequency TENS produces greater inhibition of dorsal horn neuron activity than low
frequency TENS [202]. Specifically, C-fibers are maximally suppressed at stimulation
frequencies of 80 – 100 Hz [203]. Finally, it was expected that application of TENS on
the back would cause similar decreases in BP as compared to application of TENS on the
forearm, but with less of an increase in CBF (measured in the palm), since the stimulation
current would most likely activate α2 receptors in the dorsal horn of the spinal cord more
so than at the sympathetic nerve terminals of primary afferent neurons based on the
electrode placement site.
Data for the hemodynamic parameters, pain intensity, and reperfusion time were
all analyzed in JMP Pro 11 software. Repeated measures ANOVA and Dunnett’s Test
were used for comparisons among the different treatment conditions and comparing each
treatment condition to the control, respectively. Statistical significance was accepted
when P < 0.05. P-values for all hemodynamic parameters and pain intensity are shown in
Appendix G.
5.2 Results
To test the proposed hypotheses for stimulation frequency and modality as well as
electrode placement, six different treatment conditions and a control were all compared in
terms of pain intensity, CBF in the palm and anterior brachial region, reperfusion time,
SBP, DBP, HR, MAP, and CVR in the palm and anterior brachial region. Appendix F
lists the averages obtained for control and treatment conditions. Figure 5.4 depicts the
average pain intensity for baseline, exercise, occlusion and recovery, which is based on
the Numerical Rating Scale (NRS). Figures 5.5, 5.6, and 5.8 through 5.13 depict the
percent change for each hemodynamic parameter that was measured with regards to the
specific treatment condition. Error bars from these figures have been removed for the
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sake of clarity. Figure 5.7 depicts the average reperfusion time for all treatment
conditions.
9

8

Pain Intensity

7
6

5
4

3
2
1
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Occlusion
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TENS on Arm at 100 Hz

TENS on Back at 100 Hz

TENS on Arm at 4 Hz

TENS on Back at 4 Hz

IFC on Back

IFC on Arm

Figure 5.4: Pain intensity according to the NRS during each interval for all treatment
conditions
Pain intensity was measured to determine if the ischemic pain induced by
occlusion was reduced by TENS or IFC, which would indicate either a restoration of the
oxygen supply in the ischemic region or pain modulation by activation of Aβ-fibers or a
combination of both. TENS on the back at 4 Hz and TENS on the arm at 100 Hz
exhibited higher pain intensity compared to control for baseline, exercise, occlusion, and
recovery. All baseline pain intensity values were the same besides for TENS on the arm
at 100 Hz. Pain intensity for IFC on the arm was the same as control for exercise, but
decreased during occlusion and recovery. No statistical differences were found among the
treatment conditions when compared with the control condition. However, TENS on the
arm at 4 Hz and TENS on the back at 100 Hz exhibited lower pain intensity during
exercise and occlusion, but were higher during recovery compared to control. IFC on the
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back exhibited lower pain intensity during exercise, occlusion, and recovery compared to
control.

Cutaneous Perfusion (% Change)
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TENS on Back at 4 Hz

IFC on Back

IFC on Arm

Figure 5.5: Blood flow in the left palm, measured as percent change from baseline
reading, for all treatment conditions
CBF was measured in the left palm to determine if there was a local vasodilatory
effect from TENS or IFC, which would be exhibited as a higher percentage increase in
CBF during exercise, occlusion, and recovery as compared to control. No statistical
differences were found among the treatment conditions when compared with the control
condition. However, IFC on the arm, TENS on the back at 100 Hz, and TENS on the
back at 4 Hz all trended toward higher CBF for exercise, occlusion, and recovery
compared to the control condition. TENS on the arm at 100 Hz trended toward lower
CBF during exercise compared to control, but higher CBF during recovery. TENS on the
arm at 4 Hz exhibited the opposite trend with higher CBF during exercise, but lower CBF
during recovery. IFC on the back exhibited lower CBF during both exercise and
recovery, but was still higher than control during occlusion.
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Figure 5.6: Blood flow in the left anterior brachial region, measured as percent change
from baseline reading, for all treatment conditions
CBF was measured in the anterior brachial region to correlate the changes in
perfusion occurring downstream of the occluded region, i.e. the palm, to changes
upstream of this site. For example, if CBF in the left palm decreased during occlusion,
then an increase in CBF in the left anterior brachial region would be expected, as blood
flow is being redistributed to this ischemic region. No statistical differences were found
among the treatment conditions when compared with the control condition. However,
TENS on the arm at 100 Hz, IFC on the arm, TENS on the arm at 4 Hz, and TENS on the
back at 4 Hz trended toward higher CBF values when compared to the control condition.
IFC on the back exhibited lower CBF during exercise and occlusion, but higher CBF
during recovery compared to control. TENS on the back at 100 Hz exhibited lower CBF
for exercise, occlusion, and recovery compared to control.
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Figure 5.7: Average reperfusion time, which is the time from the start of hyperemia after
occlusion to the first instance where blood flow reaches the average baseline value, for
all treatment conditions; *p < 0.05 compared to control
Reperfusion time was measured to determine, not only if blood flow increases as
a result of TENS or IFC application, but also if blood flow redistribution to the ischemic
region is improved after occlusion. TENS on the back at 4 Hz exhibited higher
reperfusion time compared to control. All other treatment conditions exhibited lower
reperfusion time compared to control with IFC on the back being significantly lower.
However, it is important to note that reperfusion time may be dependent on the
magnitude of the perfusion change from baseline during recovery e.g. TENS on the back
at 4 Hz exhibited higher perfusion during recovery than all other treatment conditions,
meaning that it is possible reperfusion time was higher for this treatment condition
because perfusion in the palm was much higher during the hyperemia stage after
occlusion and remained higher throughout, and thus taking longer to reach the average
baseline value. The same applies to IFC on the back, which exhibited the lowest
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perfusion change in the palm during recovery as compared to the other treatment

Systolic Blood Pressure (% Change)

conditions, so it would take less time to reach the average baseline value.
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Figure 5.8: Systolic blood pressure, measured as percent change from baseline reading,
for all treatment conditions
SBP was measured to determine if the metaboreflex was attenuated by TENS or
IFC, i.e. reduced SBP would indicate a possible reduction in metaboreflex activation
during a particular phase of the protocol. No statistical differences were found among the
treatment conditions when compared with the control condition. However, TENS on the
back at 100 Hz trended toward a higher SBP compared to control for exercise, occlusion,
and recovery. IFC on the back, TENS on the arm at 100 Hz, and IFC on the arm
exhibited lower SBP during exercise and recovery, but were higher during occlusion.
TENS on the back at 4 Hz exhibited the largest increase in SBP during exercise, which
then decreased during occlusion and recovery compared to control. TENS on the arm at 4
Hz exhibited lower SBP for exercise, occlusion, and recovery compared to control.
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Figure 5.9: Diastolic blood pressure, measured as percent change from baseline reading,
for all treatment conditions
DBP was measured to determine if the metaboreflex was attenuated by TENS or
IFC, i.e. reduced DBP would indicate a possible reduction in metaboreflex activation
during a particular phase of the protocol. No statistical differences were found among the
treatment conditions when compared with the control condition. However, TENS on the
arm at 4 Hz and IFC on the back trended toward a higher DBP compared to control for
exercise, occlusion, and recovery. TENS on the arm at 100 Hz and TENS on the back at
100 Hz exhibited lower DBP during exercise and recovery, but were higher during
occlusion. TENS on the back at 4 Hz exhibited the largest increase in DBP during
exercise, which then decreased during occlusion and increased during recovery compared
to control. IFC on the arm exhibited lower DBP for exercise, occlusion, and recovery
compared to control.
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Figure 5.10: Heart rate, measured as percent change from baseline reading, for all
treatment conditions
HR was measured to determine if TENS or IFC affected descending central
controls from the brain, specifically the medulla oblongata, as any significant increase or
decrease in HR would indicate activation of this region, most likely through vascular
baroreceptor reflex arcs. No statistical differences were found among the treatment
conditions when compared with the control condition. However, IFC on the back and
TENS on the arm at 100 Hz trended toward a higher HR compared to control for
exercise, occlusion, and recovery. TENS on the back at 4 Hz exhibited higher HR during
exercise and recovery, but was lower during occlusion compared to control. TENS on the
arm at 4 Hz exhibited higher HR during exercise and occlusion, but was lower during
recovery. IFC on the arm nearly mirrored the trend for the control condition. TENS on
the back at 100 Hz exhibited lower HR during exercise and occlusion, but was higher
during recovery.
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Figure 5.11: Estimated mean arterial pressure, measured as percent change from
baseline reading, for all treatment conditions
MAP was estimated as discussed in Section 5.1 to determine if the metaboreflex
was attenuated by TENS or IFC, i.e. reduced MAP would indicate a possible reduction in
metaboreflex activation during a particular phase of the protocol. No statistical
differences were found among the treatment conditions when compared with the control
condition. However, IFC on the back and TENS on the arm at 100 Hz trended toward a
lower MAP during exercise and recovery, but were higher during occlusion compared to
control. TENS on the back at 100 Hz exhibited higher MAP during occlusion and
recovery, but was lower during exercise. TENS on the back at 4 Hz exhibited the highest
increase in MAP during exercise, which then decreased during occlusion and recovery
compared to control. TENS on the arm at 4 Hz and IFC on the arm exhibited lower MAP
during exercise, occlusion, and recovery compared to control.
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Figure 5.12: Estimated cutaneous vascular resistance in the left palm, measured as
percent change from baseline reading, for all treatment conditions
CVR was estimated in the palm as discussed in Section 5.1 to determine if the
metaboreflex was attenuated by TENS or IFC i.e. reduced CVR would indicate a possible
reduction in metaboreflex activation during a particular phase of the protocol. No
statistical differences were found among the treatment conditions when compared with
the control condition. However, TENS on the back at 100 Hz, TENS on the arm at 100
Hz, TENS on the back at 4 Hz, and TENS on the arm at 4 Hz all trended toward a lower
CVR during exercise, occlusion, and recovery compared to control. IFC on the back
exhibited higher CVR during exercise and recovery, but was lower during occlusion
compared to control. IFC on the arm exhibited the opposite trend with lower CVR during
exercise and recovery, but higher CVR during occlusion compared to control.
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Figure 5.13: Estimated cutaneous vascular resistance in the left anterior brachial region,
measured as percent change from baseline reading, for all treatment conditions
CVR was estimated in the anterior brachial region to correlate the changes in
vascular resistance occurring downstream of the occluded region, i.e. the palm to changes
upstream of this site. For example, if CVR in the left palm increased during occlusion,
then a decrease in CVR in the left anterior brachial region would be expected, as blood
flow is being redistributed to this ischemic region. No statistical differences were found
among the treatment conditions when compared with the control condition. However,
TENS on the back at 100 Hz trended toward a higher CVR compared to control for
exercise, occlusion, and recovery. IFC on the back exhibited higher CVR during exercise
and occlusion, but was lower during recovery compared to control. TENS on the arm at 4
Hz exhibited higher CVR during exercise, but was lower during occlusion and recovery.
TENS on the back at 4 Hz, IFC on the arm, and TENS on the arm at 100 Hz exhibited
lower CVR during exercise, occlusion, and recovery compared to control.
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5.3 Discussion
The goal of the pre-pilot work was to optimize the design for the eventual pilot
study. The ideal parameters, i.e. frequency, pulse width, duration of treatment, and
location of application, for a given neurostimulation technique that elicit the greatest
beneficial hemodynamic changes, i.e. decreased blood pressure, increased blood flow,
and decreased vascular resistance, are not well-established. Similarly, there has been very
little research comparing the different neurostimulation techniques to one another in
terms of these changes. Thus, the primary focus of this research was to investigate what
parameters and neurostimulation technique should be used in the pilot study. Six different
treatment conditions were compared to a control condition where the electrodes were
applied to the skin but the unit was not turned on. Specifically, TENS at 4 Hz and 100
Hz, and IFC at 100 Hz were all compared. Two different locations for electrode
placement were compared, the back at the C7 and T4 dermatomes and the forearm at the
proximal and distal regions.
From the results obtained, a complete assessment of which treatment condition
worked “best” is unattainable, as the treatment conditions did not exhibit statistically
significant differences from the control condition, besides IFC on the back, which
exhibited a significantly lower reperfusion time compared to control. The reason for this
lack of statistical significance for the rest of the hemodynamic parameters is most likely
due to the small sample sizes used for the different treatment groups, rather than a lack of
effectiveness of the actual treatment. Nevertheless, the trends shown in Figures 5.4
through 5.13 suggest which treatment condition may be the most effective and which
conditions should be ruled out based on their potential adverse effects. Application of
TENS on the arm at 100 Hz trended towards increased pain intensity during exercise and
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occlusion. Although this condition trended towards increased CBF and decreased CVR,
any treatment condition that increases pain intensity compared to control should not be
utilized for the pilot study. The reason for this is that participants will be able to opt out
of the experiment if they reach their personal pain tolerance threshold, so we want to
ensure that we do not cause any additional/unnecessary pain besides the inducedischemic pain. For this same reasoning, application of TENS on the back at 4 Hz should
not be further pursued as it too trended towards increased pain intensity. It was also the
only treatment condition that trended towards a longer reperfusion time than control as
well as a higher MAP during exercise. Excluding these two treatment conditions, TENS
on the arm at 4 Hz trended towards favorable hemodynamic changes, such as lower
reperfusion time, pain intensity, CVR in the anterior brachial region and in the palm,
MAP, SBP, and higher CBF in the anterior brachial region compared to control. TENS
on the back at 100 Hz also trended towards favorable hemodynamic changes, such as
lower reperfusion time, pain intensity, CVR in the palm, HR, DBP, and higher CBF in
the palm compared to control. This is in accordance with work by Vieira et al, in which
decreases in MAP, increases in blood flow, and decreases in vascular resistance with
application of TENS on the back at 80 Hz were found in their younger aged group [81],
although MAP was higher than control during occlusion and recovery in our own study.
These results cannot be directly compared, since both the TENS parameters and
perfusion measurement instrumentation used in our study and in the study by Vieira et al
were different, e.g. blood flow was measured in the calf using venous occlusion
plethysmography rather than in the palm and anterior brachial region using LDF.
Furthermore, MAP was continuously monitored using a Dinamap blood pressure monitor
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rather than estimated from SBP and DBP. From our own results, it seems that a low
stimulation frequency is more effective when TENS is applied on the forearm, while a
high stimulation frequency is more effective when TENS is applied on the back. It was
expected that a high frequency would be more effective, regardless of electrode
placement, but it is possible that a high frequency on the forearm activates Aδ-fibers
responsible for the sharp pain sensation, which could also stimulate the SNS further. The
high frequency on the back may be more effective than a low frequency, because it is
capable of causing maximum suppression of the C-fibers, which allows for higher
intensities to be used; thus, current travels farther along the dermatomes to the ischemic
site, providing more local pain relief and vasodilation. Application of IFC on the arm
presented the most consistent beneficial hemodynamic changes compared to the other
treatment conditions, i.e. the data trended towards increased blood flow to the palm and
anterior brachial region, decreased MAP, decreased CVR in the anterior brachial region,
decreased pain intensity throughout the experiment, decreased reperfusion time, and it
did not change HR. This was expected based on the hypothesis that IFC stimulates deeper
muscle afferents, which further reduces noxious stimulus transmission and metaboreflex
activation. The only concerning aspect of this treatment condition was that CVR in the
palm increased slightly during occlusion compared to control, while all other treatment
conditions decreased during this interval, Nevertheless, CVR trended towards lower
values during exercise and recovery for IFC on the arm compared to control. Although
not shown in Figure 5.12, the standard error during the occlusion phase was large, so
there may be random effects from subject variation, or the standard error may result
solely from experimental error. Application of IFC on the back also had promising results
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with the greatest reductions in pain and CVR in the palm, as well as a significant
decrease in reperfusion time compared to control, although CBF trended towards lower
values in the palm and anterior brachial regions as compared to control. This significant
decrease in reperfusion time indicates either that blood flow redistribution to the palm
after occlusion was improved compared to control and/or that it took less time to reach
the average baseline perfusion value because the percent change during recovery was
lower than the rest of the treatment conditions. In work by Santos et al, the effect of IFC
on the back at 100 Hz was also investigated and they found statistically significant
decreases in MAP, increases in blood flow, and decreases in vascular resistance. MAP
trended towards lower values in our own study during exercise and recovery, but
increased during occlusion compared to control. Although CVR in the palm trended
towards lower values, CBF did as well, so our results do not show the same trends as
Santos’s study, although it should be noted that venous occlusion plethysmography was
used to measure blood flow in the calf and the treatment duration was 30 minutes rather
than 15 minutes [126]. Regardless, it seems that IFC did produce more favorable
hemodynamic changes overall than TENS.
While conducting the pre-pilot work, a number of potential possibilities for
experimental error were observed, all of which must be carefully considered and
addressed before performing the pilot study. The most significant error we observed were
fluctuations in blood flow readings not caused by the treatment condition itself during
some of the experiments. For example, ambient temperature affects skin temperature and
skin temperature can affect blood flow [204]. During our research, we noticed that
fluctuations in room temperature could affect the skin temperature readings that we
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recorded from the LDF system, although to what extent was not determined in our
research. Thus, blood flow may also have been affected by these fluctuations in room
temperature. In order to mitigate this potential error, skin temperature was recorded
before and after the treatment session to determine if any appreciable change had
occurred. So long as the skin temperature remained within ± 1°C, the results were kept
for that individual session. If the temperature had fluctuated beyond this range, a new
treatment session would have been conducted again and compared to the previous session
to determine if there were significant differences between the two, but this did not occur.
The blood flow readings can also be affected by any kind of motion artifact, such as from
breathing, movement of the limbs, or vibrations from other equipment/other sources.
Luckily, this motion artifact is relatively easy to identify in LabChart. For instance, major
spikes in blood flow can be seen from both skin probes if the subject moves their arm.
These spikes can be deleted from the data trace, so that they do not affect the results. The
blood flow reading will change based on where the probe is positioned, so much so that
even a millimeter difference in probe placement can affect the reading by as much as 200
perfusion units (PU). This is why percent changes from baseline must be taken for LDF
measurements, not to mention there is inter-individual variation and day-to-day variation
in these measurements as well. The reason for this day-to-day variation may be due to
prior exercise, lack of sleep, hunger, dehydration, sickness, stress, and caffeine
consumption. The blood pressure measurements that were taken for this study were not
conducted in the most ideal manner. Most current research in this field uses continuous
blood pressure monitors, such as Finometers, because they provide a real-time
measurement that can be averaged over each interval of the experiment. MAP and CVR
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can then be accurately calculated from these measurements [66, 81, 112, 126, 156]. These
systems are very expensive (~$25-30k, based on quotes obtained from ADInstruments
and Finapres), however, and could not be purchased for this study. We used a digital
blood pressure monitor, as specified in Section 5.1, which is accurate to ± 3 mmHg. The
estimation of MAP described in Section 5.1 is acceptable, so long as HR remains below
100 beats⋅minute-1 [205], and is more applicable for healthy, younger individuals [206].
Gripping of the hand dynamometer for the “exercise” portion of the treatment session did
not cause HR to rise above this level. Lastly, the TENS parameters still have not been
optimized based on the mixed results obtained, but IFC using the parameters specified in
Table 5.1 seems to be more effective based on the trends observed for each
hemodynamic parameter.
For the pilot study, it will be imperative to keep the room where the treatment
sessions will be held as controlled as possible. Because temperature can affect CBF, the
room should have a thermostat or other device capable of maintaining a constant
temperature. The room should also be clear of any audio or visual distractions that may
influence the participant’s BP, HR, etc. The potential for motion artifact should be
reduced by ensuring all cables are not overlapping with others or resting on the
participant, if possible. Participant comfort should be a primary focus during the
treatment session. In our pre-pilot work, the participant rested their arms on a pillow to
ensure comfort and that pressure was evenly distributed across the forearm from the
blood pressure cuff. Having the participant lay in a supine position may be even better for
ensuring optimal comfort, rather than having them sit in a chair during the duration of the
treatment, and was done in a few studies for this reason [81, 112, 126, 156, 207].
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However, this may induce stronger parasympathetic activity, i.e. lower BP and HR [208].
Using the new MEDITEC budget for the next school year, it may be worthwhile to
purchase a continuous blood pressure monitor, so that MAP and CVR can be calculated
with confidence, rather than estimating both. Before the pilot study is conducted, further
investigation is still needed into the relative effectiveness of IFC and TENS, and what set
of parameters produces consistent, statistically significant hemodynamic changes.
Specifically, low intensity (sensory threshold), high frequency (100 Hz) TENS and IFC
should be compared to high intensity (motor threshold), low frequency (4 Hz) TENS and
IFC. Treatment duration should also be compared at 15 minutes and 30 minutes, as well
as determining how long the hemodynamic changes last. The electrode placement sites
should be compared on the forearm and on the back as done in our pre-pilot experiments.
Blood flow in the contralateral limb and/or the calf should also be measured to determine
if neurostimulation causes systemic vasodilation or if it is only at the site of application.
Many of these parameters have been investigated in terms of analgesic effects, but not
hemodynamic effects [202, 209-211]; thus, future pre-pilot experiments should
investigate all these different parameters (Figure 5.14). This work should build off the
work conducted by our own group, when possible, so that results may be combined to
increase the overall sample size. The research conducted by our own group has shown
that both TENS and IFC may produce favorable changes on the cardiovascular system in
ischemia- induced subjects. Whether these changes have a favorable impact on patients
with actual ischemia, such as in the case of PAOD, is still yet to be seen. Thus, the pilot
study will provide important information on the use of neurostimulation to treat ischemia,
which may warrant further clinical investigation.
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Figure 5.14: Diagram detailing the pre-pilot work that still needs to be conducted and
what specific parameters should be analyzed before the pilot study
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APPENDICES
Appendix A: Summary of Select Neurostimulation Studies on Hemodynamics
Table A.1: Summary of TENS studies
Study
Author
Year

Purpose

Model
Animal/Human
Healthy/Diseased

Ter Laan [67]
2010

Assessed the effect of
TENS on cerebral
blood flow and its
potential side-effects;
investigated the effects
of varying frequency
and hyperventilation;
accounted for
differences in age and
gender
Assessed the effect of
TENS on autonomic
cardiovascular reflexes
through noninvasive
tests i.e. tilt study, cold
face stimulus,
Valsalva’s maneuver,
handgrip test, and
supine resting

Human
Healthy

Sanderson [80]
1995

Human
Healthy

Neurostimulation
Parameters Used
Intensity
Pulse width
Frequency
Duration
Location
90% of highest
tolerated current (about
10 to 35 mA)
200 µs
2, 20, 50, 100 and 120
Hz
5 minutes at each
frequency
Applied to the
dermatome at C2-C3
Motor intensity
200 µs
150 Hz
~ 35 minutes
Applied to center of
chest and back

* MAP

Endpoints *

Possible Mechanism(s) of Action

MAP; HR; CBFV;
ETCO2

Either directly affects vascular
diameter or indirectly affects
sympathetic tone

SBP; DBP; MAP;
HR

Mild effect on autonomic reflexes;
more effective during exercise when
sympathetic tone is more strongly
stimulated; possibly blocking or
interfering with vascular reflex
response within spinal cord

= Mean Arterial Pressure; HR = Heart Rate; CBFV = Cerebral Blood Flow Velocity; ETCO 2 = End-Tidal Carbon Dioxide Concentration; SBP = Systolic Blood
Pressure; DBP = Diastolic Blood Pressure
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Study
Author
Year

Purpose

Model
Animal/Human
Healthy/Diseased

Neurostimulation
Parameters Used
Intensity
Pulse width
Frequency
Duration
Location

Endpoints *

Possible Mechanism(s) of Action

Chauhan [33]
1994

Assessed whether
TENS can relieve
ischemia associated
with angina pectoris
by increasing coronary
blood flow; accounted
for gender differences
and different disease
states
Assessed effect of
TENS on the
sympathetic nervous
system; administered
naloxone to determine
if natural opioid
release could be a
possible mechanism of
action

Human
Diseased (Syndrome
X and CAD) and
“Healthy” (heart
transplant patients)

10-60 mA
300 µs
150 Hz
5 minutes
Chest near pain location

CBFV; HR; MAP;
SBP; coronary
artery diameter;
epinephrine/norepi
nephine levels

May affect coronary microvascular
tone as a result of changes in neural
tone resulting in increased coronary
blood flow; decreased sympathetic
activity within the heart

Human
Diseased
Study I: Pacinginduced angina
pectoris (Class III or
IV)
Study II: Pacinginduced angina
pectoris (Class III or
IV) and CAD

30-50 mA
200 µs
70 Hz
15 minutes
Painful area of chest

Left ventricular
afterload; SBP;
DBP; myocardial
lactate metabolism;
systemic and
pulmonary
resistance; oxygen
saturation; stroke
volume index;
cardiac index; HR;
concentrations of
epinephrine and
norpepinephrine

Study I: Decrease in sympathetic
activity due to drop in arterial levels
of epinephrine and norepineprhine;
Study II: No change in SBP or levels
of epinephrine and norepinephine; not
mediated by beta-endorphins; may
activate delta or kappa receptor
agonists

Mannheimer [36]
1990

* MAP

= Mean Arterial Pressure; HR = Heart Rate; CBFV = Coronary Blood Flow Velocity; SBP = Systolic Blood Pressure; DBP = Dias tolic Blood Pressure
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Study
Author
Year

Purpose

Model
Animal/Human
Healthy/Diseased

Sherry [66]
2001

Assessed the effect of
burst-mode TENS on
calf blood flow,
arterial pressure, and
skin temperature

Human
Healthy

Cramp [63]
2000

Assessed the effect of
both high and low
frequency TENS on
local cutaneous blood
flow and skin
temperature

Human
Healthy

* MAP

Neurostimulation
Parameters Used
Intensity
Pulse width
Frequency
Duration
Location
Motor intensity
250 µs
Burst frequency: 2
bursts per second
Carrier frequency: 85
Hz
5 minutes
Peroneal and tibial
nerves

Endpoints *

Possible Mechanism(s) of Action

CBF; MAP; skin
temperature;
ETCO2 ; BP; CVR

Depends on stimulation intensity
whereby a higher intensity can cause
muscle contraction and a transient,
local increase in blood flow via
accumulation of metabolic vasodilator
substances and/or release of “relaxing
factors” from endothelium

Sensory intensity
200 µs
Low (4 Hz) and high
(110 Hz)
15 minutes
Median nerve of
forearm

Forearm blood
perfusion; skin
temperature

Low frequency stimulation elicits a
local increase in cutaneous blood flow
as a result of vasodilation but does not
affect skin temperature; may partially
inhibit the sympathetic nervous
system

= Mean Arterial Pressure; BP = Blood Pressure; CBF = Calf Blood Flow; CVR = Calf Vascular Resistance; ETCO 2 = End-Tidal Carbon Dioxide Concentration
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Study
Author
Year

Purpose

Model
Animal/Human
Healthy/Diseased

Vieira [81]
2012

Assessed the effect of
TENS on
metaboreflex
activation and HRV in
both young and older
subjects

Human
Healthy

Indergand [207]
1994

Assessed the effect of
TENS on limb blood
flow; compared both
sensory and motor
intensities

Human
Healthy

* MAP

Neurostimulation
Parameters Used
Intensity
Pulse width
Frequency
Duration
Location
Sensory intensity
150 µs
80 Hz
30 minutes
C7 and T4 vertebral
levels

Endpoints *

Possible Mechanism(s) of Action

HR; MAP; CBF;
CVR; HRV

Both sensory and motor
intensity
150 µs
110 Hz
20 minutes
Left common peroneal
nerve and left tibial
nerve

CBF; MAP; CVR;
skin temperature

Blunted muscle metaboreflex, reduced
sympathetic activity, and
improvement of the sympatho-vagal
balance with application of TENS,
especially in younger individuals;
metaboreflex may be attenuated in
older subjects
Both sensory and motor intensity
levels of TENS failed to elicit any
changes in CBF, MAP, or CVR; skin
temperature decreased during both
control and TENS

= Mean Arterial Pressure; HR = Heart Rate; CBF = Calf Blood Flow; CVR = Calf Vascular Resistance; HRV = Heart Rate Variab ility
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Table A.2: Summary of SCS studies
Study
Author
Year

Purpose**

Model
Animal/Human
Healthy/Diseased

Tallis [37]
1983

Assessed whether
SCS could
potentially
improve clinical
outcomes for
PAOD patients;
compared to
placebo and
TENS as well
Assessed the
effect of SCS on
peripheral
vasodilation at
different
frequencies; used
RTX and CGRP8–
37 to try to
elucidate
mechanisms

Human
PAOD

Gao [97]
2010

Rats
Healthy

Neurostimulation
Parameters Used
Intensity
Pulse width
Frequency
Duration
Location
8 mA
200 µs
33 Hz
Varied on the order of
months
Not indicated

Endpoints *

Possible Mechanism(s) of Action**

Claudication distance;
exercise tolerance using
bicycle ergometer;
CBF; MBF

Inhibits vasoconstriction; antidromic
stimulation of sensory neurons may
cause release of prostaglandins and
prostacyclins in muscle

30%, 60%, and 90% of
motor intensity
200 µs
50, 200, and 500 Hz
2 minutes
L2 - L3 vertebral levels

CBF; MAP; CVR

CGRP8–37 blocks vasodilation
induced by SCS;
SCS activates TRPV1-containing
sensory neurons to release
vasodilators; indirectly induces
release of NO; both antidromic and
sympathetic inhibition mechanisms
at work; higher frequencies i.e. 500
Hz cause more vasodilation

* MAP

= Mean Arterial Pressure; CBF = Cutaneous Blood Flow; CVR = Cutaneous Vascular Resistance; CGRP = Calcitonin Gene-Related Peptide; TRPV1 =
Transient Receptor Potential Vanilloid-1; NO = Nitric Oxide; RTX = Resiniferatoxin
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Study
Author
Year

Purpose††

Model
Animal/Human
Healthy/Diseased

Augustinsson [32]
1985

Assessed the
potential for SCS
as a treatment for
PAOD and
whether it reduced
the number of
amputations

Human
PAOD/diabetic;
Buerger’s disease;
vasospastic
disorders

Croom [96]
1997

Assessed the
effect of SCS on
cutaneous
vasodilation,
specifically in
regards to the
release of CGRP
and substance P;
investigated
whether
rhizotomy of the
dorsal roots would
attenuate the
induced
vasodilation

Rats
Healthy

Neurostimulation
Parameters Used
Intensity
Pulse width
Frequency
Duration
Location
Varied
200 µs
100 Hz
~15 months
T10 vertebral level for
affected legs, T3 and
C5 for affected arms

Endpoints *

Possible Mechanism(s) of Action

SBP; skin temperature;
systolic toe pressure; pain
relief (qualitative); number
of amputations; healing of
ulcers; thumb pressure

0.2 or 0.6 mA
200 µs
50 Hz
1 minute
L1 – L2 vertebral levels

CBF; CVR; MAP

Suppresses vasospasm in addition to
pain; stimulation may cause
prostaglandin release having a local
dilatory effect on the vasculature or it
may simply block the noxious signal
which would decrease sympathetic
tone; may release segmental spinal
reflexes causing sympatholysis
within vessels in the extremities
Vasodilation caused by release of
CGRP into the periphery via
antidromic activation of sensory
afferents in the dorsal roots,
specifically L3 – L5 dorsal roots are
necessary for increased cutaneous
hindpaw blood flow; substance P
does not play a major role in the
vasodilatory response

* MAP

= Mean Arterial Pressure; CBF = Cutaneous Blood Flow; CVR = Cutaneous Vascular Resistance; CGRP = Calcitonin Gene-Related Peptide; SBP = Systolic
Blood Pressure
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Table A.3: Summary of EA studies
Study
Author
Year

Purpose

Model *
Animal/Human
Healthy/Diseased

Lin [112]
2003

Assessed whether
EA has a depressor
effect on the
cardiovascular
system

Human
Healthy

Zhou [68]
2013

Assessed whether
EA-induced
cerebral protection
against ischemia
was dependent on
stimulation of
certain acupoints

Rats
Induced cerebral
ischemia via
MCAO

Neurostimulation
Parameters Used
Intensity
Pulse width
Frequency
Duration
Location
5x above sensory intensity
50 µs
2 Hz
3 minutes
“Hoku” point (LI-4) i.e.
between index finger and
thumb

Endpoints *

Possible Mechanism(s) of Action

BP, PVT, FBF, HR

Increased PVT explained by decreased
response of sympathetic nerve system,
which caused dilation of arterioles; BP
and FBF decreased while HR increased

1 mA
500 µs
5 Hz or 20 Hz
30 minutes
4 different acupoints: DU26 & DU-20, left LI-11 &
PC-6, right LI-11 & PC-6,
and left GB-34 & SP-6 i.e.
head, face, anterior limbs

Infarct volume; death
rate; neurological
deficits; CBF

Location of stimulation can have a
protective effect against cerebral
ischemia possibly via regulation of
neurotransmitter release, causing an
increase in blood flow, but only in
ischemic conditions

*CBF

= Cerebral Blood Flow; BP = Blood Pressure; PVT = Paravertebral Temperature; FBF = Finger Blood Flow; HR = Heart Rate; MCAO = Middle Cerebral Artery
Occlusion
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Study
Author
Year

Purpose

Model *
Animal/Human
Healthy/Diseased

Noguchi
[113]
1999

Assessed whether
EA stimulation
could induce
changes in muscle
blood flow and
determined which
somatic afferent
fibers were
responsible for
these changes

Rats
Healthy

Kimura [64]
2008

Assessed the effect
of EA on the
rhythmicity of the
autonomic nervous
system

Canine Healthy

Neurostimulation
Parameters Used
Intensity
Pulse width
Frequency
Duration
Location
0.1-10 mA
500 µs
1-20 Hz
30 seconds
Left and right hindpaws

Endpoints *

Possible Mechanism(s) of Action

MBF; MAP; RBF

5V
250 µs
2 Hz
15 minutes
“Xuan Shu” (GV-5) and
“Bai Hui” (GV-20) i.e. T13L1 and L7-S1 spinal
segment levels

HR; CVRR; LF/HF;
HRV

Stimulation of group III and IV
afferent fibers in saphenous and tibial
nerves produces an increase in MBF in
conjunction with an increase in
systemic MAP; splanchnic nerve
severance decreases MBF suggesting
group III and IV afferent fibers
primarily excite a vasoconstrictive
response; the pressor response still
dominates in muscles causing more
vasodilation than vasoconstriction;
stimulation of group I and II afferent
fibers seems to be ineffective
Activates sympathetic nervous
activities as evidenced by increase in
LF/HF ratio

*MAP

= Mean Arterial Pressure; HR = Heart Rate; RBF = Renal Blood Flow; MBF = Muscle Blood Flow; CVRR = Coefficient of Variati on in R-R Intervals; LF/HF =
Low-Frequency/High Frequency (components of HRV); HRV = Heart Rate Variability
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Table A.4: Summary of IFC studies
Study
Author
Year

Purpose

Model
Animal/Human
Healthy/Diseased

Johnson [119]
2003

Assessed the analgesic
effects of both IFC
and TENS on induced
ischemic pain

Human
Healthy

Noble [125]
2000

Assessed the effect of
varying frequency of
IFC on CBF

Human
Healthy

Santos [126]
2013

Assessed the effect of
IFC on muscle
metaboreflex
activation and
peripheral vasodilation

Human
Healthy

Neurostimulation
Parameters Used
Intensity
Pulse width
Frequency
Duration
Location
Sensory intensity
200 µs
100 Hz
22 minutes
Anterior and posterior
aspects of forearm

Endpoints *

Possible Mechanism(s) of Action

Amount of pain
experienced (VAS &
MPQ scores)

Selective activation of A-beta
nerve fibers

Sensory intensity
125 µs
10-100, 80-100, and 10-20
Hz
15 minutes
Medial and lateral aspects of
the thigh
Sensory intensity
Not indicated
100 Hz
30 minutes
C7 and T4 spinal segments

Skin temperature; CBF

Low frequency (10-20 Hz) causes
increases in CBF and skin
temperature through inhibition of
the sympathetic nervous system

MAP; HR; CBF; CVR;
metaboreflex activity

Decrease in MAP and metaboreflex
activity indicates reduction in
sympathetic tone; reduced CVR
and increased CBF

*MAP

= Mean Arterial Pressure; HR = Heart Rate; RBF = Renal Blood Flow; MBF = Muscle Blood Flow; CVRR = Coefficient of Variati on in R-R Intervals; LF/HF =
Low-Frequency/High Frequency (components of HRV); HRV = Heart Rate Variability
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Appendix B: Informed Consent Form
INFORMED CONSENT TO PARTICIPATE IN A RESEARCH PROJECT: “Determining Limb
Blood Flow Changes in Response to Electrical Neurostimulation”.
A research project on peripheral blood flow and ischemic pain is being conducted by
Sean Youra and Stacey Fishman in the Department of Biomedical Engineering at Cal Poly, San
Luis Obispo. The purpose of the study is to measure changes in blood flow, heart rate, and blood
pressure due to the application of electrical neurostimulation.
You are being asked to take part in this study by first filling out a short medical history
questionnaire. Questions marked with an asterisk (*) are required, but any others you do not wish
to answer may be omitted. These questions are directly related to your safety. During each
treatment session, you will be hooked up to a neurostimulation device that will be attached to
your upper back with electrodes, a blood flow measurement system using skin probes on the
upper arms, a respiration belt wrapped around your midsection, and a blood pressure cuff applied
to each arm. Appropriate clothing should be worn to ensure proper placement of the electrodes,
and a researcher from the same gender will be there to place the electrodes on your upper back.
You will be asked to squeeze a handgrip force measurement device for a short period of time.
You will experience electrical stimulation from the attached electrodes, which you may feel as a
warm, tingling sensation on your back. Your participation will take approximately 1 hour in two
separate sessions on two different days, which includes a 30-minute break in-between each
session, for a total of approximately 2 hours. In some of these sessions, the neurostimulation
device will be hooked up to you, but no current will be applied, as in you will not feel any
sensation on your back. This will be randomized. Please be aware that you are not required to
participate in this research and you may discontinue your participation at any time without
penalty.
The possible risks associated with participation in this study include pain due to
temporarily induced ischemia i.e. insufficient blood flow to the tissue, skin irritation from the
application of skin probes and electrodes, and possible discomfort and/or stress from gripping the
hand force measurement device. If your personal pain tolerance threshold is reached at any point,
you may discontinue your participation immediately. If you should experience residual pain or
tingling after the duration of the experiment or an allergic reaction at the site of the probes or
electrodes, please be aware that you may contact Cal Poly Health and Counseling Services,
located in building 27, at (805) 756-1211 for assistance.
Your confidentiality will be protected by recording your medical history, age, gender,
height and weight on a document with a corresponding code. This document will be kept as a
hard copy only and separate from the corresponding list of codes. Your information will only be
accessible to the researchers in this study. If the results of the study are published, any identifying
information will be omitted. There are no direct benefits to you associated with this study.
Depending on the outcome of the study, this could become an additional treatment method for
individuals with ischemic pain.
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If you have questions regarding this study or would like to be informed of the results
when the study is completed, please feel free to contact Sean Youra at (949) 697-5789, Stacey
Fishman at (860) 338-4085, or Dr. Trevor Cardinal at (805) 756-6244. If you have concerns
regarding the manner in which the study is conducted, you may contact Dr. Steve Davis, Chair of
the Cal Poly Human Subjects Committee, at (805) 756-2754, sdavis@calpoly.edu, or Dr. Dean
Wendt, Interim Dean of Research, at (805) 756-1508, dwendt@calpoly.edu.
If you agree to voluntarily participate in this research project as described, please indicate
your agreement by signing below. Please keep one copy of this form for your reference, and
thank you for your participation in this research.

____________________________________ ________________
Signature of Volunteer

Date

____________________________________ ________________
Signature of Researcher

Date
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Appendix C: Medical History And Screening Form
* Required

General Information
Participant:

Sex:




Women only answer the following:
Yes No

 
 
Men and women answer the following:

_______________________________________________________________________
_______________________________________________________________________

_______________________________________________________________________

_______________________________________________________________________
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Past Medical History
* Required
Have you ever had any of the following:
Yes No

































Smoking





Drinking
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Appendix D: Numeric Pain Rating Scale
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Appendix E: Protocol For The Pilot Study
 Setup






Turn on the laptop.
Connect the power supply to PowerLab.
Connect the USB cable from PowerLab to the laptop.
Connect the respiration belt to Input 1 on the front panel of PowerLab.
Connect the Hand Dynamometer to Input 2 on the front panel of
PowerLab.
 Connect the power supply to the Laser Doppler Flow (LDF) system and
turn it on.
 Connect the skin probes to Channels 1 and 2 on the LDF system.
 Connect the BNC cables from the LDF system to Inputs 3 and 4 on the
front panel of PowerLab.
 Turn on the PowerLab system.
 Open LabChart on the laptop and open the customized settings file.
 The raw breath signal in millivolts (mV), the respiratory rate in breaths per
minute (BPM), the handgrip force in Newtons (N), CBF 1 in perfusion
units (PU), and CBF 2 in PU should all be displayed in LabChart at this
point.
 Application
 Seat the participant in a chair with both arms supinated and gently resting
on the pillow. Ensure that they are comfortable and properly positioned
before continuing.
 Instruct the participant to loosely grip the Hand Dynamometer in the fist
of their left hand.
 Instruct the participant to squeeze the Hand Dynamometer as hard as
possible for a second or two, and then relax their grip.*
 Determine Maximum Voluntary Contraction (MVC) by recording the
average of three handgrip trials and calculate 25% of MVC.
 Apply the TENS electrodes to the C7 and T4 vertebrae locations,
approximately 3 cm to the left and right of the vertebral column (Figure
4.4).†

* Adapted from BMED 460 – “Muscle Stimulation Fatigue Student Protocol” by Trevor Cardinal
† Adapted

from "Effect of transcutaneous electrical nerve stimulation on muscle metaboreflex in healthy
young and older subjects." by Vieira, et. al.
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Figure D.1: TENS Electrode Placement at the C7 and T4 Regions*
 Wrap the respiration belt around the participant’s chest, just below the
xiphoid process.
 Attach the skin probe connected to Channel 1 of the LDF system to the
left arm, 2 cm below the crease of the wrist.
 Attach the skin probe connected to Channel 2 of the LDF system to the
right arm, 2 cm below the crease of the wrist.
 Wrap the cuff connected to the manual sphygmomanometer around the
participant’s left forearm, 2 cm below the crease of the elbow.
 Wrap the cuff connected to the blood pressure monitor around the
participant’s right arm.
 Set the stimulation frequency to 100 Hz, pulse duration to 200 μs, and
slowly adjust the intensity to just above sensory threshold (no pain or
muscle contraction) by asking the participant when he/she begins to feel a
strong, but comfortable tingling sensation.
 Treatment
 Begin treatment according to assigned group code. †
 Every minute, assess the intensity of the participant’s pain via the NPRS.
In addition, halfway through each interval of the treatment i.e. “baseline”,

* Adapted from "Effect of transcutaneous electrical nerve stimulation on muscle metaboreflex in healthy

young and older subjects." by Vieira, et. al.
† Group

codes: Control/PECO- (CP-), Control/PECO+ (CP+), TENS/PECO- (TP-), TENS/PECO+ (TP+)
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* Only if PECO+

“exercise”, “occlusion”, and “recovery”, record the participant’s blood
pressure and heart rate from the monitor.
Begin recording baseline blood flow for 3 minutes.
Place the hand dynamometer in the participant’s left hand. Instruct the
participant to perform a static handgrip exercise for 3 minutes at 25%
MVC.
Five seconds before exercise completion, inflate the sphygmomanometer
cuff to 180 mmHg.*
Maintain cuff inflation at 180 mmHg for 3 minutes, while still recording
blood flow.
Deflate the cuff immediately and record for 3 minutes.
Stop recording.
Insert comments for “baseline”, “exercise”, “occlusion”, and “recovery” at
the end of each interval.
Detach all equipment from the participant and wait at least 30 minutes
before beginning the next treatment.

group
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Appendix F: Averages From Pre-Pilot Work
Table F.1: Average percent change for all hemodynamic parameters for each treatment
condition
Exercise
Control (n = 20)
CBF 1
CBF 2
SBP
DBP
HR
MAP
CVR 1
CVR 2
TENS Application
on the Back at High
Frequency (n = 6)
CBF 1
CBF 2
SBP
DBP
HR
MAP
CVR 1
CVR 2
TENS Application
on the Forearm at
High Frequency (n
= 2)
CBF 1
CBF 2
SBP
DBP
HR
MAP
CVR 1
CVR 2
TENS Application
on the Back at Low
Frequency (n = 2)
CBF 1
CBF 2
SBP
DBP
HR

Occlusion

Recovery

20.61408
6.181795
4.922132
4.045545
4.116884
4.343151
1.979512
-1.34234

-90.1396
10.56105
2.513589
4.212532
4.732632
3.420077
1258.739
-3.54692

70.7512
-7.52406
1.065731
2.391328
-0.72447
1.658637
-36.7768
12.89023

25.43661
-5.5738
6.04962
0.036075
2.698413
2.595939
-18.2172
11.68384

-81.5803
-12.4239
5.324572
5.411255
-2.43386
5.37299
570.4271
21.19491

185.0897
-8.40812
5.120653
-0.03608
2.195767
2.147184
-54.2402
13.07613

16.45631
17.8305
0.81187
3.159981
8.249337
2.145089
-5.08757
-12.8027

-80.0942
24.17139
2.874207
5.538713
6.618037
4.337402
597.8964
-13.8696

114.3978
2.384457
-4.04069
0.034981
2.122016
-1.7909
-45.3314
-3.84971

84.16821
14.21466
10.29571
9.732163
9.254386

-77.4402
14.37029
-3.0833
2.34357
2.675439

259.6295
4.612285
0.531915
2.574463
5.921053
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MAP
CVR 1
CVR 2
TENS Application
on the Forearm at
Low Frequency (n
= 2)
CBF 1
CBF 2
SBP
DBP
HR
MAP
CVR 1
CVR 2
IFC Application on
the Back (n = 2)
CBF 1
CBF 2
SBP
DBP
HR
MAP
CVR 1
CVR 2
IFC Application on
the Forearm (n = 4)
CBF 1
CBF 2
SBP
DBP
HR
MAP
CVR 1
CVR 2

9.975071
-10.7307
-3.47213

-0.03917
802.1998
-10.4482

1.698718
-52.9969
-2.73357

44.57743
5.046217
0.423812
6.737288
4.312039
3.67893
-16.3281
0.07898

-82.7889
19.99818
-5.45535
4.265537
5.454545
-0.19509
1184.719
-16.9482

72.09013
-6.70987
-1.87759
3.418079
-5.42998
1.161278
-34.5453
9.427779

-15.2391
1.131429
-1.40911
6.299841
13.95161
2.753674
25.3756
1.982277

-80.6055
-1.04201
6.140351
5.023923
8.225806
5.581614
445.1115
6.688098

3.330334
-0.52675
-0.90519
2.232855
8.252688
0.869684
0.364934
2.013535

68.73909
20.54841
3.632479
-4.3794
2.255727
-0.92894
-10.8726
-16.7931

-89.7606
37.41265
6.452991
1.947623
8.625526
4.044313
1518.964
-20.5259

117.8071
5.370384
3.076923
-2.26673
-1.6129
0
-43.7508
-2.40704
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Appendix G: Statistical Analysis
Table G.1: Two-way Repeated Measures ANOVA P-values for Hemodynamic Endpoints
Baseline

Exercise

Occlusion

Recovery

CBF 1

-

0.5962

0.0525

0.2257

CBF 2

-

0.4950

0.4691

0.9333

SBP

-

0.5827

0.7223

0.8479

DBP

-

0.4988

0.9417

0.8843

HR

-

0.4601

0.9878

0.2911

MAP

-

0.2122

0.8725

0.7789

CVR 1

-

0.8997

0.3380

0.3474

CVR 2

-

0.3535

0.2601

0.6502

Pain Intensity

0.0817

0.0654

0.2176

0.3325

P-value
Reperfusion Time

0.039*

* Dunnett’s Test Comparison: IFC on Back significantly different from control
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